Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
Novel dihydropyrrolo[3,4-C]pyrazole derivatives enable high-affinity PET imaging of alpha-synuclein aggregates, addressing the limitations of current imaging agents and enhancing the diagnosis and monitoring of alpha-synucleinopathies like Parkinson's disease.
Patent Information
- Application Number
- JP2024527406
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-10
- Filing Date
- 2022-11-10
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current imaging agents for alpha-synuclein aggregates, such as those associated with Parkinson's disease, lack sufficient affinity and selectivity, making accurate diagnosis and monitoring of alpha-synucleinopathies challenging.
Development of novel dihydropyrrolo[3,4-C]pyrazole derivatives and their detectably labeled compounds that bind to alpha-synuclein aggregates with high affinity, enabling positron emission tomography (PET) imaging for diagnosing and monitoring diseases like Parkinson's disease.
These compounds provide accurate imaging of alpha-synuclein aggregates, allowing for early detection, monitoring disease progression, and predicting treatment responsiveness, thereby improving diagnostic accuracy and therapeutic management of alpha-synucleinopathies.
Smart Images

Figure 2024544521000001 
Figure 2024544521000002 
Figure 2024544521000003
Abstract
Description
[Technical field]
[0001] The present invention relates to novel compounds of formula (I) or detectably labeled compounds thereof, stereoisomers, racemic mixtures, pharma- ceutically acceptable salts, hydrates or solvates that can be used to image and determine the amount of alpha-synuclein aggregates.Furthermore, the compounds can be used to diagnose diseases, disorders or disorders associated with alpha-synuclein (α-synuclein, A-synuclein, a-synuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including but not limited to Lewy bodies and / or Lewy neurites, to determine predisposition to such diseases, disorders or disorders, to prognose such diseases, disorders or disorders, to monitor the progression of diseases in patients suffering from such diseases, disorders or disorders, to monitor the progression of such diseases, disorders or disorders, and to predict the responsiveness of patients suffering from such diseases, disorders or disorders to treatment. The invention also relates to methods for preparing the compounds and their precursors, diagnostic compositions comprising the compounds, methods of using the compounds, kits comprising the compounds and uses thereof. [Background technology]
[0002] Many age-related diseases are based on or associated with extracellular or intracellular deposition of amyloid or amyloid-like proteins that contribute to the pathogenesis and progression of the disease. The best-characterized amyloid protein that forms extracellular aggregates is amyloid beta (Abeta or Aβ).
[0003] Amyloid-like proteins that form primarily intracellular aggregates include, but are not limited to, tau, alpha-synuclein, and huntingtin (HTT). Diseases associated with alpha-synuclein aggregates are generally listed as synucleinopathies (or alpha-synucleinopathies), including, but not limited to, Parkinson's disease (PD). Synucleinopathies involving primarily neuronal aggregates include, but are not limited to, Parkinson's disease (sporadic, familial with SNCA (the gene encoding the alpha-synuclein protein) mutations or SNCA gene duplications or triplications, familial with mutations in other genes but not SNCA, pure autonomic failure and Lewy body dysphagia), SNCA duplication carriers, dementia with Lewy bodies (LBD), dementia with Lewy bodies (DLB) ("pure" Lewy body dementia), Parkinson's disease dementia (PDD), diffuse Lewy body disease (DLBD), Alzheimer's disease, sporadic Alzheimer's disease, familial Alzheimer's disease with APP mutations, familial Alzheimer's disease with PS-1, PS-2 or other mutations, familial British dementia, Lewy body variant of Alzheimer's disease, and normal aging in Down's syndrome. Synucleinopathies involving neuronal and glial aggregates of alpha-synuclein include, but are not limited to, multiple system atrophy (MSA) (Shy-Drager syndrome, striatonigral degeneration, and olivopontocerebellar atrophy). Other diseases that may have alpha-synuclein-immunoreactive lesions include traumatic brain injury, chronic traumatic encephalopathy, dementia pugilistica, tauopathies (Pick's disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration and Niemann-Pick disease type C1, frontotemporal dementia with parkinsonism linked to chromosome 17), motor neuron diseases, Huntington's disease, amyotrophic lateral sclerosis (sporadic, familial and Guam ALS-dementia complex), neuroaxonal dystrophies, neurodegeneration type 1 with cerebral iron accumulation (Hallervorden-Spatz syndrome), prion diseases, Creutzfeldt-Jakob disease, ataxia-telangiectasia, Meige syndrome, subacute sclerosing panencephalitis, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, Gaucher disease, Krabbe disease,and other lysosomal storage disorders (including Kufor-Rakeb syndrome and Sanfilippo syndrome) and rapid eye movement (REM) sleep behavior disorder, but are not limited to these (Jellinger, Mov. Disord. 2003, 18 Suppl. 6, S2-12; Galvin et al. JAMA Neurology 2001, 58 (2), 186-190; Kovari et al. Acta Neuropathol. 2007, 114(3), 295-8; Saito et al. J. Neuropathol. Exp. Neurol. 2004, 63(4), 323-328; McKee et al. Brain 2013, 136(Pt 1), 43-64; Puschmann et al. Parkinsonism Relat. Disord. 2012, 18S1, S24-S27; Usenovic et al., J. Neurosci. 2012, 32(12), 4240-4246; Winder-Rhodes et al., Mov. Disord. 2012, 27(2), 312-315; Ferman et al., J. Int. Neuropsychol. Soc. 2002, 8(7), 907-914; Smith et al., J. Pathol. 2014;232:509-521; Lippa et al., Ann Neurol. 1999 March;45(3):353-7; Schmitz et al., Mol. Neurobiol. 2018 August 22; Charles et al., Neurosci. Lett. 2000 July 28;289(1):29-32;Wilhelmsen et al., Arch Neurol. 2004 March;61(3):398-406;Yamaguchi et al., J. Neuropathol Exp. Neurol. 2004, 80th Annual Meeting, Vol. 63;Askanas et al., J. Neuropathol Exp. Neurol. 2000 July;59(7):592-8).
[0004] Alpha-synuclein is a naturally occurring unfolded protein of 140 amino acids (Iwai et al., Biochemistry 1995, 34(32), 10139-10145). The sequence of alpha-synuclein can be divided into three main domains: 1) the N-terminal region, including residues 1-60, containing an 11-mer amphipathic imperfect repeat with a highly conserved hexamer (KTKEGV). This region has been implicated in regulating the binding of alpha-synuclein to membranes and its internalization; 2) the hydrophobic non-amyloid beta component (NAC) domain, spanning residues 61-95, which is essential for alpha-synuclein fibrillization; and 3) the C-terminal region, spanning residues 96-140, which is highly acidic and proline-rich and has no unique structural propensities. Alpha-synuclein has been shown to undergo several post-translational modifications, including truncation, phosphorylation, ubiquitination, oxidation and / or transglutaminase covalent cross-linking (Fujiwara et al., Nat. Cell. Biol. 2002, 4(2); 160-164; Hasegawa et al., J. Biol. Chem. 2002, 277(50), 49071-49076; Li et al., Proc. Natl. Acad. Sci. USA 2005, 102(6), 2162-2167; Oueslati et al., Prog. Brain Res. 2010, 183, 115-145; Schmid et al., J. Biol. Chem. 2009, 284(19), 13128-13142). Interestingly, the majority of these modifications involve residues within the C-terminal region.
[0005] Several phosphorylation sites have been detected in the carboxyl-terminal region at Tyr-125, -133 and -136, and at Ser-129 (Negro et al., FASEB. J 2002, 16(2), 210-212). The Tyr-125 residue can be phosphorylated by two Src family protein tyrosine kinases, c-Src and Fyn (Ellis et al., J. Biol. Chem. 2001, 276(6), 3879-3884; Nakamura et al., Biochem. Biophys. Res. Commun. 2001, 280(4), 1085-1092). Phosphorylation by Src family kinases does not inhibit or enhance the tendency of alpha-synuclein to polymerize. Alpha-synuclein is phosphorylated in vitro by the protein tyrosine kinase p72 sykAlpha-synuclein has been shown to be an excellent substrate for alpha-synuclein kinase A (Syk), and when it is extensively Tyr-phosphorylated by Syk or tyrosine kinases with similar specificity, it loses its ability to form oligomers, suggesting a putative role for these tyrosine kinases in preventing neurodegeneration (Negro et al., FASEB J. 2002, 16(2), 210-212). Alpha-synuclein can be Ser-phosphorylated by the protein kinases CKI and CKII (Okochi et al., J. Biol. Chem. 2000, 275(1), 390-397). Residue Ser-129 is also phosphorylated by G-protein-coupled receptor protein kinases (Pronin et al., J. Biol. Chem. 2000, 275(34), 26515-26522). Extensive and selective phosphorylation of alpha-synuclein at Ser-129 is evident in synucleinopathy lesions, including Lewy bodies (Fujiwara et al., Nat. Cell. Biol. 2002, 4(2); 160-164). Other post-translational modifications at the carboxyl-terminus, including glycosylation at Ser-129 (McLean et al., Neurosci Lett. 2002, 323(3), 219-223) and nitration at Tyr-125, -133, and -136 (Takahashi et al., Brain Res. 2002, 938(1-2), 73-80), may affect the aggregation of alpha-synuclein. Proteolytic truncation of the carboxyl-terminal region has been reported to play a role in alpha-synuclein fibril development in various neurodegenerative diseases (Rochet et al., Biochemistry 2000, 39(35), 10619-10626). Full-length as well as partially truncated insoluble aggregates of alpha-synuclein have been detected in highly purified Lewy bodies (Crowther et al., FEBS Lett. 1998, 436(3), 309-312).
[0006] Abnormal protein aggregation appears to be a common feature of the aging brain and in several neurodegenerative diseases (Trojanowski et al. 1998, Cell Death Differ. 1998, 5(10), 832-837; Koo et al., Proc. Natl. Acad. Sci. 1999, 96(18), 9989-9990; Hu et al., Chin.Sci.Bull. 2001, 46, 1-3); however, a clear role in disease processes remains elusive. In in vitro models, alpha-synuclein (or some of its truncated forms) readily assembles into filaments that resemble those isolated from the brains of patients with Lewy body (LB) dementia and familial PD (Crowther et al., FEBS Lett. 1998, 436(3), 309-312). Alpha-synuclein and its mutant forms (A53T and A30P) have a random coil conformation and do not form significant secondary structures at low concentrations in aqueous solution. However, at high concentrations, they tend to self-aggregate and generate amyloid fibrils (Wood et al., J. Biol. Chem. 1999, 274(28), 19509-19512). Some differences in the aggregation behavior of mutant and wild-type proteins associated with PD have been documented. Monomeric alpha-synuclein aggregates form stable fibrils in vitro via a metastable oligomeric (i.e. prefibrillar) state (Volles et al., Biochemistry 2002, 41(14), 4595-4602).
[0007] Parkinson's disease (PD) is the most common neurodegenerative movement disorder. PD is primarily an idiopathic disease, but in at least 5% of PD patients, the pathology is associated with mutations in one or several specific genes. Several point mutations have been described in the alpha-synuclein gene (A30P, E46K, H50Q, G51D, A53T) causing familial PD with autosomal dominant inheritance. Furthermore, duplications and triplications of the alpha-synuclein gene have been described in patients developing PD, emphasizing the role of alpha-synuclein in PD pathogenesis (Lesage et al., Hum. Mol. Genet., 2009, 18, R48-59). The etiology of PD remains unclear. However, growing evidence suggests a role for pathogenic misfolding of the alpha-synuclein protein that leads to the formation of amyloid-like fibrils. Indeed, the hallmark of PD is the presence of intracellular alpha-synuclein aggregate structures, called Lewy bodies and neurites, primarily in substantia nigra neurons, and the death of dopaminergic neurons in the substantia nigra and elsewhere. Alpha-synuclein is a naturally unfolded presynaptic protein that can misfold and aggregate into large oligomeric and fibrillar forms, which have been linked to the pathogenesis of PD. Recent studies have implicated small soluble oligomeric and prefibrillar forms of alpha-synuclein as the most neurotoxic species (Lashuel et al., J. Mol. Biol., 2002, 322, 1089-102). However, the exact role of alpha-synuclein in neuronal toxicity remains to be elucidated (reviewed in: Cookson, Annu. Rev. Biochem., 2005, 74, 29-52).
[0008] In addition to Parkinson's disease, accumulation of aggregated alpha-synuclein into Lewy bodies is a characteristic of all Lewy body diseases, including Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) (Capouch et al., Neurol. Ther. 2018, 7, 249-263). In DLB, Lewy bodies are widely distributed throughout the brain cortex, and in addition to Lewy bodies and neurites, many thread-like and punctate structures (Lewy puncta) have been found to be immunopositive for alpha-synuclein phosphorylated at Ser-129 (Outeiro et al., Mol. Neurodegener. 2019, 14, 5). Alpha-synuclein aggregates are also found in multiple system atrophy (MSA). MSA is a rare, sporadic neurodegenerative disorder that manifests with rapidly progressive autonomic and motor dysfunction and heterogeneous cognitive decline. Such disorders include Shy-Drager syndrome, striatonigral degeneration and olivopontocerebellar atrophy. The disease can be clinically subclassified into parkinsonian (MSA-P) or cerebellar (MSA-C) variants depending on the predominant motor phenotype (Fanciulli et al., N. Engl. J. Med. 2015;372, 249-63). It is characterized by aggregation of alpha-synuclein in the cytoplasm of oligodendrocytes forming glial cytoplasmic inclusions (GCIs). GCIs, consisting mainly of fibrillar forms of alpha-synuclein, are the neuropathological hallmark of MSA and are found throughout the neocortex, hippocampus, brainstem, spinal cord and dorsal root ganglia (Galvin et al., Arch Neurol. 2001,58, 186-90). GCIs are thought to play a central role in the pathogenesis of MSA. Correlations between GCI amount and the degree of neuronal loss have been reported in both striatonigral and olivopontocerebellar regions (Stefanova et al., Neuropathol Appl Neurobiol. 2016, 42, 20-32). Furthermore, a causal link between GCI and the induction of neuronal loss has been shown in transgenic mice overexpressing human alpha-synuclein in oligodendrocytes under various oligodendrocyte-specific promoters.A key event in the pathophysiological cascade appears to be the permissive templating ('prion-like' propagation) of misfolded alpha-synuclein.
[0009] The diagnosis of Parkinson's disease is largely clinical and depends on the presence of a specific set of symptoms and signs (early cardinal features are bradykinesia, rigidity, rest tremor and postural instability), the absence of irregular features, a slowly evolving course and a response to symptomatic drug treatment, mainly limited to dopamine replacement therapy. Accurate diagnosis requires sophisticated clinical techniques and is subject to a degree of subjectivity and error, since several other degenerative and non-degenerative diseases can mimic PD symptoms (multiple system atrophy (MSA), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), essential tremor, dystonic tremor) (Guideline No. 113: Diagnosis and pharmacological management of Parkinson's disease, January 2010. SIGN). Definitive confirmation of the lesion can only be made by postmortem neuropathological analysis.
[0010] Computed tomography (CT) and conventional magnetic resonance imaging (MRI) brain scans of people with Parkinson's disease (PD) usually appear normal. These techniques are nevertheless useful in ruling out other diseases that may be secondary causes of parkinsonism, such as basal ganglia tumors, vascular lesions, and hydrocephalus. A specific technique of MRI, diffusion MRI, has been reported to be useful in distinguishing between typical and atypical parkinsonism, although its exact diagnostic value is still under investigation. Dopaminergic function in the basal ganglia can be measured using different PET and SPECT radiotracers. Examples include isoflurane ( 123 I) (brand name DaTSCAN) and Iometopane (Dopascan), or fluorodeoxyglucose ( 18 F)( 18 F-FDG) and dihydrotetrabenazine ( 11 C) ( 11A pattern of reduced dopaminergic activity in the basal ganglia can help diagnose PD, especially during the symptomatic stage (Brooks, J. Nucl. Med., 2010, 51, 596-609; Redmond, Neuroscientist, 2002, 8, 457-88; Wood, Nat. Rev. Neurol., 2014, 10, 305).
[0011] Strategies are being developed to apply recent advances in understanding the underlying causes of Parkinson's disease to the development of biochemical biomarkers (Schapira Curr. Opin. Neurol. 2013;26(4):395-400). Such biomarkers investigated in different body fluids (cerebrospinal fluid (CSF), plasma, saliva) include not only alpha-synuclein levels, but also DJ-1, tau and Abeta, as well as neurofilament proteins, interleukins, osteopontin and hypocretin (Schapira Curr. Opin. Neurol. 2013;26(4):395-400), but so far none of these biomarkers, alone or in combination, can be used as a definitive diagnostic test. To the best of our knowledge, despite the critical need for Parkinson's disease research and drug development, no approved alpha-synuclein diagnostics are currently on the market or available for clinical trials (Eberling et al., J Parkinsons Dis. 2013;3(4):565-7).
[0012] The ability to image alpha-synuclein deposits in the brain would be a major advance for alpha-synucleopathy research, including Parkinson's disease research, diagnosis, and drug development. Accumulation of aggregated alpha-synuclein in the brain is considered a key pathological hallmark of Parkinson's disease (PD) and can start years before the appearance of symptoms. Thus, alpha-synuclein is a priority target for drug development, not only considering its possible contribution to neurodegeneration, but also offering the possibility of treating what is still in the asymptomatic or presymptomatic stages of the disease. In vivo imaging of alpha-synuclein pathology could be useful as a biomarker (i) to potentially detect the presence of disease at an early stage, (ii) to assess disease progression, and (iii) to be used as a pharmacodynamic tool for drug development. The development of alpha-synuclein PET imaging agents is now considered important for the accurate diagnosis of synucleinopathies and to support the clinical development of alpha-synuclein-targeting therapeutics, starting with the ideal selection of a study population (Eberling, Dave and Frasier, J. Parkinson's Disease, 3, 565-567 (2013)). Despite numerous attempts to identify alpha-synuclein PET ligands, only compounds that bind to artificial alpha-synuclein fibrils with reasonably high affinity have been identified so far, but none of them have been validated in human clinical trials.These are not ideal for several reasons: low affinity or no binding has been observed with pathological aggregates of alpha-synuclein present in diseased brains, there is reportedly little or no selectivity for alpha-synuclein over other aggregated proteins, and the physicochemical properties are inadequate for use as brain-penetrating PET agents (Eberling et al., J Parkinsons Dis. 2013;3(4):565-7; Neal et al., Mol. Imaging Biol. 2013,15:585-595; Bagchi et al., PLoS One 2013,8(2):e55031; Yu et al., Bioorganic and Medicinal chemistry 2012,20:4625-4634; Zhang et al., Appl Sci(Basel) 2014,4(1):66-78; Chu et al., J. Med. Chem., 2015, 58(15):6002-17).
[0013] WO2011 / 128455 refers to certain compounds suitable for treating disorders associated with amyloid proteins or amyloid-like proteins. US Patent Application Publication No. 2012 / 0302755 relates to certain imaging agents for detecting neurological dysfunction. Further compounds for diagnosing neurodegenerative disorders in the olfactory epithelium are discussed in WO2012 / 037928.
[0014] WO2010 / 063701 refers to an in vivo imaging agent for use in a method for determining the presence of or susceptibility to Parkinson's disease, the in vivo imaging agent comprising an alpha-synuclein binding agent labelled with an in vivo imaging moiety, the in vivo imaging agent binding to alpha-synuclein with binding affinity.
[0015] US2014 / 0142089 relates to a method for preventing or treating a degenerative brain disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a particular compound, its pharma- ceutically acceptable salts, isomers, solvates, hydrates, and combinations thereof.
[0016] WO2009 / 155017 describes aryl or heteroaryl substituted azabenzoxazole derivatives which are said to be useful as tracers in positron emission tomography (PET) imaging to study amyloid deposits in the brain in vivo and enable the diagnosis of Alzheimer's disease.
[0017] WO2016 / 033445 refers to certain compounds for imaging huntingtin protein.
[0018] WO2017 / 153601, WO2019 / 234243 and WO2021 / 224489 refer to bicyclic compounds for diagnosing a-synuclein aggregates. [Prior art documents] [Patent documents]
[0019] [Patent Document 1] WO2011 / 128455 [Patent Document 2] US Patent Application Publication No. 2012 / 0302755 [Patent Document 3] WO2012 / 037928 [Patent Document 4] WO2010 / 063701 [Patent Document 5] US Patent Application Publication No. 2014 / 0142089 [Patent Document 6] WO2009 / 155017 [Patent Document 7] WO2016 / 033445 [Patent Document 8] WO2017 / 153601 [Patent Document 9] WO2019 / 234243 [Patent Document 10] WO2021 / 224489 [Non-Patent Document]
[0020] [Non-Patent Document 1] Jellinger, Mov. Disord. 2003, 18 Suppl. 6, S2 - 12 [Non-Patent Document 2] Galvin et al., JAMA Neurology 2001, 58(2), 186 - 190 [Non-Patent Document 3] Kovari et al., Acta Neuropathol. 2007, 114(3), 295 - 298 [Non-Patent Document 4] Saito et al., J. Neuropathol. Exp. Neurol. 2004, 63(4), 323 - 328 [Non-Patent Document 5] McKee et al., Brain, 2013, 136(Pt 1), 43 - 64 [Non-Patent Document 6] Puschmann et al., Parkinsonism Relat. Disord. 2012, 18S1, S24 - S27 [Non-Patent Document 7] Usenovic et al., J. Neurosci. 2012, 32(12), 4240 - 4246 [Non-Patent Document 8] Winder-Rhodes et al., Mov. Disord. 2012, 27(2), 312 - 315 [Non-Patent Document 9] Ferman et al., J. Int. Neuropsychol. Soc. 2002, 8(7), 907 - 914 [Non-Patent Document 10] Smith et al., J. Pathol. 2014; 232:509 - 521 [Non-Patent Document 11] Lippa et al., Ann Neurol. March 1999;45(3):353-357
Non-Patent Document 12
Non-Patent Document 13
Non-Patent Document 14
Non-Patent Document 15
Non-Patent Document 16
Non-Patent Document 17
Non-Patent Document 18
Non-Patent Document 19
Non-Patent Document 20
Non-Patent Document 21
Non-Patent Document 22
Non-Patent Document 23
Non-Patent Document 36
Non-Patent Document 37
Non-Patent Document 38
Non-Patent Document 39
Non-Patent Document 40
Non-Patent Document 41
Non-Patent Document 42
Non-Patent Document 43
Non-Patent Document 44
Non-Patent Document 45
Non-Patent Document 46
Non-Patent Document 47
Non - Patent Document 48
Non - Patent Document 49
Non - Patent Document 50
Non - Patent Document 51
Non - Patent Document 52
Non - Patent Document 53
Non - Patent Document 54
Non - Patent Document 55
Non - Patent Document 56
Non - Patent Document 57
Non - Patent Document 58
Non - Patent Document 59
[0021] Thus, there is a need for a new class of imaging compounds that bind to alpha-synuclein with reasonably high affinity. [Means for solving the problem]
[0022] The present invention provides compounds that can be used for the diagnosis of diseases, disorders or disorders associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites (e.g., Parkinson's disease), for determining the prognosis of such diseases, disorders or disorders, and for monitoring the progression of such diseases, disorders or disorders. In particular, the compounds should be suitable for determining the predisposition to such diseases, disorders or disorders, for monitoring the progression of such diseases, disorders or disorders, or for predicting the responsiveness of patients suffering from such diseases, disorders or disorders to treatment with a certain pharmaceutical agent. Furthermore, the compounds should be suitable for the diagnosis of diseases, disorders or disorders associated with alpha-synuclein aggregates, and / or for the detection and optionally quantification of alpha-synuclein aggregates.
[0023] Various embodiments of the present invention are described herein.
[0024] Within certain embodiments, the compound of formula (I):
[0025] [ka]
[0026] (In the formula,
[0027] [ka]
[0028] is a 6-membered heteroaryl; X is CH or N; R 1is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl), wherein C1-C4 alkyl is optionally substituted with at least one halo, or at least one H attached to the N in -NH2 or -NH(C1-C4 alkyl) is replaced with halo, or R 1 is haloC1-C4 alkoxy, R 2 is optionally a 5- or 6-membered heteroaryl substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy, and -C1-C4 alkyl), or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate, or solvate thereof.
[0029] In another aspect, the present invention provides a compound having the subformula
[0030] [ka]
[0031] or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0032] In one aspect, the present invention provides a diagnostic composition comprising a compound of formula (I) and, optionally, at least one pharma- ceutically acceptable excipient, carrier, diluent and / or adjuvant.
[0033] In one aspect, the present invention provides a compound of formula (I) or a diagnostic composition as defined herein, which may be for use in imaging alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. In another aspect, the compound of formula (I) or a diagnostic composition may be for use in positron emission tomography imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. In another aspect, the compound of formula (I) or a diagnostic composition as defined herein may be for in vitro imaging, ex vivo imaging or in vivo imaging, preferably the use is for in vivo imaging, more preferably the use is for brain imaging. In yet another aspect, the compound of formula (I) or a diagnostic composition as defined herein may be for use in a diagnostic method.
[0034] In a further aspect, the invention provides a method of diagnosing a disease, disorder or abnormality associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a subject, comprising: (a) administering to a subject a compound of formula (I), or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites; and (c) detecting compounds that bind to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites. This refers to a method including:
[0035] In another aspect, the invention provides a method of positron emission tomography (PET) imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject, comprising: (a) administering to a subject a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein. (b) binding the compound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites; and (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, by acquiring positron emission tomography (PET) images of the subject's tissue. This refers to a method including:
[0036] In a further aspect, the invention provides a method for detecting, and optionally quantifying, alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject, comprising: (a) contacting a sample or a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally quantifying the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The present invention relates to a method comprising:
[0037] The present invention provides a method of collecting data for diagnosing a disease, disorder, or abnormality associated with alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample or a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region. The present invention also covers a method including the steps of:
[0038] The present invention provides a method of collecting data to determine a predisposition to a disease, disorder, or condition associated with alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample or a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region. The present invention also relates to a method comprising the steps of:
[0039] In a further aspect, the invention provides a method of collecting data for prognosing a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample, a particular body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The present invention also relates to a method comprising the steps of:
[0040] In another aspect, the invention provides a method of collecting data to monitor the progression of a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a patient, comprising: (a) contacting a sample, a particular body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The present invention relates to a method comprising:
[0041] In a further aspect, the present invention provides a method of collecting data to predict responsiveness to a pharmaceutical agent in a patient suffering from a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample, a particular body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of formula (I) or a diagnostic composition comprising a compound of formula (I) as defined herein; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The present invention relates to a method comprising the steps of:
[0042] In another aspect, the present invention relates to a compound of formula (III-F)
[0043] [ka]
[0044] (In the formula,
[0045] [ka]
[0046] is a 6-membered heteroaryl; X is CH or N; R 1F is a 4- to 7-membered heterocyclyl; or R 1F is -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), or R 1F is C1-C4 alkoxy, R 2is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; LG is a leaving group, n is at least 1, preferably 1), or a stereoisomer, a racemic mixture, a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0047] In another aspect, the present invention relates to a compound of formula (III-H)
[0048] [ka]
[0049] (In the formula,
[0050] [ka]
[0051] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), or R 1 is fluoro C1-C4 alkoxy, R 2is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; m is 0, 1 or 2; p is 0, 1 or 2; Z is bromo, chloro or iodo; -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy or -C1-C4 alkyl optionally contains at least one Z; With the proviso that the compound of formula (III-H) contains at least one Z, or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0052] In another aspect, the present invention relates to a compound of formula (III-F) 18 The present invention is further directed to a process for preparing a compound of formula (IF) by reacting with an F-fluorinating agent.
[0053] In another aspect, the present invention relates to a compound of formula (III-H): 3 The present invention is further directed to a method of preparing a compound of formula (IH) by reacting with a 3 H radiolabeling agent.
[0054] In another aspect, the present invention is further directed to the use of the compounds of formula (I) as in vitro analytical standards or in vitro screening tools.
[0055] In another aspect, the present invention is further directed to a test kit for detecting and / or diagnosing a disease, disorder or abnormality associated with alpha-synuclein aggregates, the test kit comprising at least one compound of formula (I) as defined herein.
[0056] The present invention is further directed to a kit for preparing a radiopharmaceutical preparation, the kit comprising a sealed vial containing at least one compound of Formula (III-F) or (III-H).
[0057] definition For purposes of interpreting this specification, the following definitions shall apply unless otherwise specified and where appropriate, and terms used in the singular shall include the plural and vice versa. It should also be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "the compound" includes reference to one or more compounds, and so forth.
[0058] The term "C1-C4 alkyl" refers to a saturated straight or branched hydrocarbon chain containing no unsaturation, having from 1 to 4 carbon atoms, and consisting solely of carbon and hydrogen atoms, attached to the remainder of the molecule by a single bond. Examples of suitable alkyl groups having from 1 to 4 carbon atoms include, but are not limited to, methyl, ethyl, propyl, isopropyl, 1-methylethyl, n-butyl, t-butyl, and isobutyl.
[0059] The term "C1-C4 alkoxy" refers to a group of formula -ORa, where Ra is a C1-C4 alkyl group as generally defined above. Examples of C1-C4 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy and isobutoxy.
[0060] The term "halogen C1-C4 alkyl" or "halo C1-C4 alkyl" refers to a C1-C4 alkyl group as defined above that is substituted with one or more halo groups as defined below. Examples of "halo C1-C4 alkyl" include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,3-dibromopropan-2-yl, 3-bromo-2-fluoropropyl, and 1,4,4-trifluorobutan-2-yl.
[0061] The term "halogen C1-C4 alkoxy" refers to a C1-C4 alkoxy group as defined above that is substituted with one or more halo groups as defined below. Examples of "halo C1-C4 alkoxy" include, but are not limited to, trifluoromethoxy, difluoromethoxy, fluoromethoxy, 2,2,2-trifluoroethoxy, 3,3,3-trifluoropropoxy, 4,4,4-trifluorobutoxy, 2,2-difluorobutoxy, and 4-bromobutoxy.
[0062] The term "heterocyclyl" refers to a stable 4- to 6-membered non-aromatic monocyclic ring group containing one or two heteroatoms selected from, for example, N, O, or S. Heterocyclyl groups can be unsaturated or saturated. Heterocyclyl groups can be attached via a carbon atom or a heteroatom. Examples include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl, piperazinyl, tetrahydropyranyl, or morpholinyl, preferably azetidinyl, pyrrolidinyl, or piperidinyl.
[0063] The term "heteroaryl" refers to a six-membered aromatic monocyclic ring containing one, two or three heteroatoms independently selected from N, O and S. The heteroaryl group can be attached via a carbon atom or a heteroatom selected from N, O and S. Examples of heteroaryl include, but are not limited to, thiopyranyl, dioxanyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidyl or pyridyl.
[0064] The term "Hal" or "halogen" or "halo" refers to F, Cl, Br and I. For diagnostic and medical applications, F (e.g. 19 F and 18 F) is particularly preferred.
[0065] The term "leaving group" (LG) as used herein means any leaving group, an atom or group of atoms that can be replaced by another atom or group of atoms. Examples are, for example, Synthesis (1982), pp. 85-125, table 2; Carey and Sundberg, Organische Synthese (1995), pp. 279-281, table 5.8; or Netscher, Recent Res. Dev. Org. Chem., 2003, pp. 7, 71-83, schemes 1, 2, 10 and 15, etc.). (Coenen, Fluorine-18 Labeling Methods: Features and Possibilities of Basic Reactions (2006), Schubiger PA, Friebe M., Lehmann L. (Eds.), PET-Chemistry - The Driving Force in Molecular Imaging. Springer, Berlin Heidelberg, pp. 15-50, scheme 4 on p. 25, scheme 5 on p. 28, table 4 on p. 30, and FIG. 7 on p. 33). Preferably, the "leaving group" (LG) is a halogen, C 1~ C4 alkyl sulfonates and C 6~ C 10 aryl sulfonates, C 6~ C 10 The arylsulfonates can be optionally substituted with -CH3 or -NO2.
[0066] Unless otherwise specified, the term "compound of the invention" refers to a compound of formula (I) or a subformula thereof (e.g., (IIa), (IIb), (IIa'), (IIb'), (IIa"), (IIb"), (IF), (IH)), or a detectably labeled compound thereof, stereoisomer (including diastereoisomeric mixtures and individual diastereoisomers, enantiomeric mixtures and single enantiomers, mixtures of conformers and single conformers), racemic mixture, pharma- ceutically acceptable salt, hydrate, or solvate thereof. It is understood that each reference to a compound of formula (I) as defined herein also covers its subformulas (e.g., (IIa), (IIb), (IIa'), (IIb'), (IIa"), (IIb"), (IF), (IH)). Compounds of formula (III-F) and (III-H) are referred to as precursors of the compounds of the invention.
[0067] The compounds of the present invention and their precursors having one or more optically active carbons may exist as racemates and racemic mixtures, stereoisomers (including diastereomeric mixtures and individual diastereoisomers, enantiomeric mixtures and single enantiomers, mixtures of conformers and single conformers), tautomers, atropisomers and rotamers. All isomeric forms are included in the present invention.
[0068] "Pharmaceutically acceptable salts" are defined as derivatives of the disclosed compounds where the unchanged form has been modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues, such as amines; alkali or organic salts of acidic residues, such as carboxylic acids, and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the unchanged form, formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids, such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; and organic acids, such as, but not limited to, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, and the like. Pharmaceutically acceptable salts of the compounds of the present invention and their precursors can be synthesized from the unchanged form containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Organic solvents include, but are not limited to, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile. A list of suitable salts can be found in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, PA, 1990, page 1445, the disclosure of which is hereby incorporated by reference.
[0069] "Pharmaceutically acceptable" is defined as those compounds, materials, compositions and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals, within the bounds of medical good sense, without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0070] "Solvates" may be formed from the compounds of the invention and any suitable pharma- ceutically acceptable solvent. Examples include C1-4 alcohols (e.g., methanol or ethanol).
[0071] The patient or subject in the present invention is typically an animal, particularly a mammal, and more particularly a human.
[0072] Alpha-synuclein aggregates are multimeric beta-sheet-rich assemblies of alpha-synuclein monomers that can form soluble oligomers or soluble / insoluble prefibrils or mature fibrils, associated with intracellular deposits detected as various Lewy pathologies in Parkinson's disease and other synucleinopathies. Alpha-synuclein aggregates constituting Lewy pathologies can be detected as having the following morphologies: Lewy bodies, Lewy neurites, immature Lewy bodies or pale bodies, perikarya deposits with diffuse, granular, punctate or polymorphous patterns. Furthermore, alpha-synuclein aggregates are the main component of intracellular fibrillar inclusions (also called glial cytoplasmic inclusions) detected in oligodendrocytes, as well as intracellular fibrillar inclusions (called neuronal cytoplasmic inclusions) in neuronal cell bodies, axons and nuclei, which are histological hallmarks of multiple system atrophy. Alpha-synuclein aggregates in Lewy pathology often display a substantial increase in post-translational modifications, such as phosphorylation, ubiquitination, nitration and truncation.
[0073] Lewy bodies are abnormal aggregates of proteins that develop inside nerve cells in Parkinson's disease (PD), dementia with Lewy bodies, and other synucleinopathies. Lewy bodies appear as spherical masses that replace other cellular components. Morphologically, Lewy bodies can be classified as brainstem or cortical type. Typical brainstem Lewy bodies are eosinophilic cytoplasmic inclusions consisting of a dense core surrounded by a 5-10 nm wide halo of radial fibers, the main structural component of which is alpha-synuclein. Cortical type Lewy bodies differ in the absence of the halo. The presence of Lewy bodies is a hallmark of Parkinson's disease.
[0074] Lewy neurites are abnormal neuronal processes in pathological neurons that contain granules, abnormal alpha-synuclein (a-syn) filaments similar to those found in Lewy bodies, punctate varicose structures and axonal spheroids. Like Lewy bodies, Lewy neurites are a hallmark of α-synucleinopathies, such as dementia with Lewy bodies, Parkinson's disease and multiple system atrophy.
[0075] The terms "disease," "disorder," or "condition" are used interchangeably herein.
[0076] The compound of formula (I) can bind to alpha-synuclein aggregates. The type of binding with the compound of formula (I) is not elucidated, and any type of binding is covered by the present invention. The terms "compounds that bind to alpha-synuclein aggregates" and the like are used interchangeably herein and are not considered to be limited to any particular type of binding.
[0077] The preferred definitions provided in the "Definitions" section apply to all of the embodiments described below unless otherwise specified. Various embodiments of the invention are described herein, and it is recognized that the features specified in each embodiment may be combined with other specified features to obtain further embodiments of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0078] The compounds of the present invention and their precursors are described below. It is to be understood that all possible combinations of the following definitions are also contemplated.
[0079] The present invention relates to a compound represented by formula (I)
[0080] [ka]
[0081] (In the formula,
[0082] [ka]
[0083] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl), wherein C1-C4 alkyl is optionally substituted with at least one halo, or at least one H attached to the N in -NH2 or -NH(C1-C4 alkyl) is replaced with halo, or R 1 is haloC1-C4 alkoxy, R 2 is a 5- or 6-membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl), or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0084] In one embodiment, the present invention provides a method for the preparation of a compound of formula (I):
[0085] [ka]
[0086] (In the formula,
[0087] [ka]
[0088] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2, or -NH(C1-C4 alkyl), wherein C1-C4 alkyl is optionally substituted with at least one halo; R 2 is a 5- or 6-membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl), or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0089] In another embodiment, the present invention relates to a compound represented by formula (IIa) or (IIb)
[0090] [ka]
[0091] or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, having the formula (I):
[0092] Preferably, the present invention relates to a compound of formula (IIa'), (IIa"), (IIb') or (IIb")
[0093] [ka]
[0094] or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, having the formula (I):
[0095] In one embodiment, R 1 is -NH2, -N(C1-C4 alkyl)2, or -NH(C1-C4 alkyl), where C1-C4 alkyl is optionally substituted with at least one halo, or at least one H attached to the N in -NH2 or -NH(C1-C4 alkyl) is replaced with halo. In further embodiments, R 1 is -NH, -N(C1-C4 alkyl) or -NH(C1-C4 alkyl), where C1-C4 alkyl is optionally substituted with at least one halo (e.g., 1, 2 or 3 halo, preferably 1 or 2 halo). 1 is -NH2, -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl). In a preferred embodiment, R 1 is -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl).
[0096] In another preferred embodiment, R 1 is haloC1-C4 alkoxy.
[0097] In another embodiment, R 1is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo. 1 is a 4- to 6-membered heterocyclyl optionally substituted with at least one halo. Preferably, the heterocyclyl is substituted with at least one halo, more preferably with one or two halo, even more preferably with one halo. In one embodiment, the halo is F, more preferably F is 19 F or 18 F, even more preferably 18 It's F.
[0098] In another embodiment, R 1 is as follows:
[0099] [ka]
[0100] (In the formula, R 1a is a 4- to 6-membered heterocyclyl selected from H or halo, preferably halo.
[0101] In a preferred embodiment, R 1 is as follows:
[0102] [ka]
[0103] (In the formula, R 1a is a 4- or 5-membered heterocyclyl selected from H or halo, preferably halo.
[0104] In a preferred embodiment, R 1 and R 1a The halo in is F. Preferably, F is 19 F or 18 F, more preferably 18 It's F.
[0105] In yet another embodiment, R1 is as follows:
[0106] [ka]
[0107] Preferably, F is a 4- or 5-membered heterocyclyl selected from 19 F or 18 F, more preferably 18 It's F.
[0108] In yet another embodiment, R 1 teeth,
[0109] [ka]
[0110] (In the formula, R 1a is a 7-membered heterocyclyl selected from H or halo, preferably halo. In a preferred embodiment, R 1a The halo in is F. Preferably, F is 19 F or 18 F, more preferably 18 It's F.
[0111] In yet another embodiment, R 1 is the formula
[0112] [ka]
[0113] is a seven-membered heterocyclyl.
[0114] In yet another embodiment, R 1 teeth,
[0115] [ka]
[0116] and m is an integer from 1 to 4, preferably 1 or 2, and more preferably 2.
[0117] In one embodiment, R 2 is a 5- or 6-membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl.
[0118] In a preferred embodiment, R 2 is as follows:
[0119] [ka]
[0120] (In the formula, R 2a is independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; R 2b is selected from -H, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; s is a 5- or 6-membered heteroaryl selected from 0, 1 or 2, preferably 0 or 1.
[0121] Preferably, R 2 is as follows:
[0122] [ka]
[0123] (In the formula, R 2a is independently selected from haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy, and -C1-C4 alkyl; R 2b is selected from -H and C1-C4 alkyl; s is a 5- or 6-membered heteroaryl selected from 0, 1 or 2 (preferably 0 or 1).
[0124] More preferably, R 2 is as follows:
[0125] [ka]
[0126] (In the formula, R 2a is selected from -H, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; R 2b is selected from -H and -C1 to C4 alkyl).
[0127] Preferably, R 2a are independently -OCH, -CH or -H, preferably R 2b is -H or -CH3.
[0128] In one embodiment, the present invention provides a compound of formula (I) as defined herein above, or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein the compound is
[0129] [ka]
[0130] [ka]
[0131] is selected from.
[0132] In one embodiment, the present invention provides a compound of formula (I), wherein the compound of formula (I) is a detectably labeled compound. The detectable label may be a radioisotope. In one embodiment, the compound of formula (I) comprises at least one radioisotope. Preferably, the detectable label is 18 F, 2 H and 3 H. Most preferably, the radioisotope is selected from: 18 F and 3 H.
[0133] In one embodiment, the present invention provides a compound of formula (I), the compound having the formula (IF)
[0134] [ka]
[0135] (In the formula,
[0136] [ka]
[0137] is a 6-membered heteroaryl; X is CH or N; R 1F is a 4- to 6-membered heterocyclyl or a 7-membered heterocyclyl; or R 1F is -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl), or R 1F is C1-C4 alkoxy, R 2is a detectably labeled compound, or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl), -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl.
[0138] In one embodiment, the compound of formula (I) has the formula (IF)
[0139] [ka]
[0140] (In the formula,
[0141] [ka]
[0142] is a 6-membered heteroaryl; X is CH or N; R 1F is a 4- to 6-membered heterocyclyl, or R 1F is -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl), or R 1F is C1-C4 alkoxy, R 2is a detectably labeled compound, or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl), -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl.
[0143] In a preferred embodiment, R 1F is a 4- to 6-membered heterocyclyl, or a 7-membered heterocyclyl.
[0144] Preferably, -R 1F - 18 F is as follows:
[0145] [ka]
[0146] is selected from.
[0147] -R 1F - 18 F is
[0148] [ka]
[0149] It may also be selected from:
[0150] More preferably, R 1F is a 4- or 5-membered or 7-membered heterocyclyl. For example, -R 1F - 18 F is as follows:
[0151] [ka]
[0152] is selected from.
[0153] In another preferred embodiment, -R 1F - 18 F is
[0154] [ka]
[0155] It is.
[0156] The detectably labeled compound of formula (IF) comprises at least one 18 F. Preferably, the detectably labeled compound of formula (IF) comprises one 18 Contains F.
[0157] In one embodiment, the present invention provides a compound of formula (I), the compound having the formula (IH * )
[0158] [ka]
[0159] (In the formula,
[0160] [ka]
[0161] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), or R 1 is haloC1-C4 alkoxy, R2 is a 5- or 6-membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; However, the formula (IH * ) compound is at least one 2 H (deuterium "D") or 3 H (tritium "T"), preferably T (preferably containing one, two or three D or T), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0162] In one embodiment, the present invention provides a compound of formula (I), the compound having the formula (IH * )
[0163] [ka]
[0164] (In the formula,
[0165] [ka]
[0166] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), R 2is a 5- or 6-membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; However, the formula (IH * ) is present in at least one 2 H (deuterium "D") or 3 H (tritium "T"), preferably T (preferably containing one, two or three D or T), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0167] In a preferred embodiment, the compound has the formula (IH)
[0168] [ka]
[0169] (In the formula,
[0170] [ka]
[0171] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6- or 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), or R 1 is haloC1-C4 alkoxy, R 2is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; Z is T or CT3; m is 0, 1, 2 or 3; p is 0, 1, 2 or 3; With the proviso that the compound of formula (IH) contains at least one T or CT3, T is 3 3H (tritium)), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0172] In a preferred embodiment, the compound has the formula (IH)
[0173] [ka]
[0174] (In the formula,
[0175] [ka]
[0176] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), R 2is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; Z is T or CT3; m is 0, 1, 2 or 3; p is 0, 1, 2 or 3; With the proviso that the compound of formula (IH) contains at least one T or CT3, T is 3 3H (tritium)), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0177] It is understood that the tritium may be present in any available position where a hydrogen is present. For example, R 2 In the group, there may be a tritium bonded directly to the 5- or 6-membered heteroaryl (e.g., in the form of T), or the tritium may be present in -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy, and -C1-C4 alkyl (e.g., in the form of CT3). 1 In the case of a 4- to 6-membered heterocyclyl of the formula: the tritium may, for example, be directly attached to the 4- to 6-membered heterocyclyl.
[0178] In one embodiment,
[0179] [ka]
[0180] is a 6-membered heteroaryl and m is 1, 2 or 3, for example 1.
[0181] In one embodiment, R 2 is a 5- or 6-membered heteroaryl optionally substituted with 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl, and p is 1, 2 or 3, for example 1.
[0182] In a preferred embodiment, R 2 is a 5- or 6-membered heteroaryl ring,
[0183] [ka]
[0184] (In the formula, R 2a is independently selected from -H, -T, -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; R 2b is selected from -H, -T, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl (e.g., CT3); s is 0, 1 or 2 (preferably 0 or 1); -N(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl), -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl or -C1-C4 alkoxy optionally containing one or more T.
[0185] Preferably, R 2 is a 5- or 6-membered heteroaryl ring,
[0186] [ka]
[0187] (In the formula, R 2a is independently selected from -H, -T, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy, and -C1-C4 alkyl; R 2b is selected from -H, -T, -C1-C4 alkyl (e.g., CT3), preferably R 2b is selected from T or CT3, s is 0, 1 or 2 (preferably 1); haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl or -C1-C4 alkoxy optionally containing one or more T.
[0188] More preferably, R 2 is as follows:
[0189] [ka]
[0190] (In the formula, R 2a is selected from -T, -H, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl (e.g., CT3); R 2b is selected from -H, -T and -C1-C4 alkyl (e.g., CT3), preferably R 2b is selected from T or CT3, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl or -C1-C4 alkoxy optionally containing one or more T.
[0191] Preferably, R 2a is -T, -OCH3, -CH3 or -H, R2b is selected from -H or -CT3.
[0192] In a preferred embodiment, the compound of formula (IH * Detectably labeled compounds of formula (IH) or (IH) contain one, two or three T's. * ) or (IH) comprises one T. More preferably, the detectably labeled compound of formula (IH * ) or (IH) comprises two T's. Even more preferably, the detectably labeled compound of formula (IH * ) or (IH), the detectably labeled compound contains three T's, e.g., -CT3.
[0193] In another embodiment, the present invention provides a compound of formula (IH * (IH) or (IH), 3 H Tritium ("T") 2 H may be replaced by deuterium ("D"). A deuterated compound is a compound of formula (III-H) 2 It can be prepared by reacting with a 3 H radiolabeled agent.
[0194] The compounds of the present invention and their precursors can be detectably labeled. The type of label is not specifically limited and depends on the detection method selected. Examples of possible labels include isotopes, such as radionuclides, positron emitters and gamma emitters, and preferably, the detectable label is a radioisotope. For the detectably labeled compounds of the present invention and their precursors that contain a radioisotope, positron emitter or gamma emitter, it should be understood that the radioisotope, positron emitter or gamma emitter must be present in an amount that is not the same as the natural amount of the radioisotope, positron emitter or gamma emitter, respectively. Furthermore, the amount used should allow their detection by the detection method selected. Examples of suitable isotopes, such as radionuclides, positron emitters and gamma emitters, are: 2 H, 3 H, 18 F, 11 C. 13 N and15 O, preferably 2 H, 3 H, 11 C. 13 N, 15 O and 18 F, more preferably 2 H, 3 H and 18 F, even more preferably 3 H and 18 Contains F.
[0195] 18 F-labeled compounds are particularly suitable for imaging applications, such as PET. 19 The corresponding compounds containing fluorine, which have the F isotope, are also 18 They are of particular interest because they can be used as analytical standards and criteria during manufacture, quality control, release, and clinical use of the F-analogues.
[0196] Additionally, isotopes such as deuterium, i.e. 2 Substitution with H offers certain diagnostic and therapeutic advantages due to increased metabolic stability, for example, through reduced defluorination, increased in vivo half-life, or reduced dosing requirements, while maintaining or improving the efficacy of the original compound.
[0197] Isotopic variations of the compounds of the present invention and precursors thereof can generally be prepared by conventional procedures, e.g., using appropriate isotopic variations of suitable reagents that are commercially available or prepared by known synthetic techniques, by the illustrative methods or preparations described in the Examples and Preparations.
[0198] Radionuclides, positron emitters and gamma emitters can be included in the compounds of the present invention and their precursors by methods common in the field of organic synthesis.Typically, they are introduced by using correspondingly labeled starting materials when preparing the desired compounds of the present invention and their precursors.Exemplary methods of introducing detectable labels are described, for example, in US2012 / 0302755.
[0199] The position at which the detectable label should be attached to the compounds of the present invention and their precursors is not particularly limited. Radionuclides, positron emitters and gamma emitters, for example, can be attached at any position at which the corresponding non-emitting atom can also be attached. For example, 18 F may be attached at any position suitable for attaching F. The same applies to other radionuclides, positron emitters and gamma emitters. For ease of synthesis, R 1 teeth 18 It is replaced by F. 3 H can be attached at any available position where H occurs. 2 When H is used as the detectable label, it can be attached at any available position where H occurs.
[0200] In another embodiment, the present invention relates to a compound of formula (III-F) which is a precursor of the compound of formula (IF)
[0201] [ka]
[0202] (In the formula,
[0203] [ka]
[0204] is a 6-membered heteroaryl; X is CH or N; R 1F is a 4- to 6- or 7-membered heterocyclyl; or R 1F is -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), or R 1F is C1-C4 alkoxy, R 2is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; LG is a leaving group, N is at least 1) or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0205] In another embodiment, the present invention relates to a compound of formula (III-F) which is a precursor of the compound of formula (IF)
[0206] [ka]
[0207] (In the formula,
[0208] [ka]
[0209] is a 6-membered heteroaryl; X is CH or N; R 1F is a 4- to 6-membered heterocyclyl, or R 1F is -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), R 2 is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; LG is a leaving group, n is at least 1), or a stereoisomer, a racemic mixture, a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0210] Preferably, R 1F is -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl). More preferably, R 1F is -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl) or C1-C4 alkoxy.
[0211] In another preferred embodiment, R 1F is a 4- to 6- or 7-membered heterocyclyl. Preferably, (LG) n -R 1F is as follows:
[0212] [ka]
[0213] is selected from.
[0214] More preferably, (LG) n -R 1F is as follows:
[0215] [ka]
[0216] is selected from.
[0217] In yet another embodiment, R 1 teeth,
[0218] [ka]
[0219] and m is an integer from 1 to 4, preferably 1 or 2, and more preferably 2.
[0220] Preferably, the leaving group (LG) is a halogen, a C1-C4 alkylsulfonate, a C1-C4 alkylammonium or a C6-C 10 Aryl sulfonate, C6-C 10 The arylsulfonate may be optionally substituted with -CH3 or -NO2. More preferably, the leaving group (LG) is bromo, chloro, iodo, C6-C4 alkylsulfonate or C6-C 10 Aryl sulfonate, C6-C 10 The arylsulfonate may be optionally substituted with -CH3 or -NO2. Even more preferably, the leaving group (LG) is mesylate, tosylate or nosylate. Even more preferably, the leaving group (LG) is mesylate or nosylate. More preferably, the leaving group (LG) is mesylate.
[0221] In another embodiment, the present invention provides a precursor of the compound of formula (IH), formula (III-H):
[0222] [ka]
[0223] (In the formula,
[0224] [ka]
[0225] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6- or 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl), or R 1 is haloC1-C4 alkoxy, R2 is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; m is 0, 1 or 2; p is 0, 1 or 2; Z is bromo, chloro or iodo; With the proviso that the compound of formula (III-H) contains at least one Z (e.g., one, two or three Z, preferably one or two Z), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0226] In another embodiment, the present invention provides a precursor of the compound of formula (IH), formula (III-H):
[0227] [ka]
[0228] (In the formula,
[0229] [ka]
[0230] is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6-membered heterocyclyl optionally substituted with at least one halo; or R 1 is -NH2, -N(C1-C4 alkyl)2 or -NH(C1-C4 alkyl), R 2is a 5- or 6-membered heteroaryl optionally substituted by 1 or 2 substituents independently selected from -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; m is 0, 1 or 2; p is 0, 1 or 2; Z is bromo, chloro or iodo; With the proviso that the compound of formula (III-H) contains at least one Z (e.g., one, two or three Z, preferably one or two Z), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0231] In a preferred embodiment, (Z) p -R 2 is as follows:
[0232] [ka]
[0233] (In the formula, R 2a is independently selected from -H, -Z, -halo, -OH, -CN, -N(C1-C4 alkyl)2, -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl)2, -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; R 2b is selected from -H, -Z, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkoxy and -C1-C4 alkyl; s is 0, 1 or 2 (preferably 0 or 1); -N(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(haloC1-C4 alkyl), -NH(haloC1-C4 alkyl), haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl or -C1-C4 alkoxy optionally containing one or more Z).
[0234] Preferably, (Z) p -R 2 is as follows:
[0235] [ka]
[0236] (In the formula, R 2a is independently selected from -H, -Z, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl, and -C1-C4 alkoxy; R 2b is selected from -H, -Z and -C1-C4 alkyl, preferably -Z; s is 0, 1 or 2 (preferably 0 or 1); haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl or -C1-C4 alkoxy optionally containing one or more Z.
[0237] More preferably, (Z) p -R 2 is as follows:
[0238] [ka]
[0239] (In the formula, R 2a is selected from -H, -Z, haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl, and -C1-C4 alkoxy; R 2b is selected from -H, -Z and -C1-C4 alkyl; s is 0, 1 or 2 (preferably 0 or 1); haloC1-C4 alkyl, haloC1-C4 alkoxy, -C1-C4 alkyl or -C1-C4 alkoxy optionally containing one or more Z.
[0240] In a preferred embodiment, the detectably labeled compound of formula (III-H) comprises one, two or three Z. In a preferred embodiment, the detectably labeled compound of formula (III-H) comprises one Z. In another preferred embodiment, the detectably labeled compound of formula (III-H) comprises two Z. In one embodiment, Z is selected from bromo, chloro and iodo. In a preferred embodiment, Z is bromine.
[0241] Methods for synthesizing detectably labeled compounds The present invention relates to compounds of formula (I) or subformulas thereof (e.g., (IIa), (IIb), (IIa'), (IIb'), (IIa"), (IIb"), (IF), (IH), * The present invention further relates to methods for preparing compounds of formula (III-F) or (III-H) that contain a detectable label.
[0242] In one embodiment, the present invention relates to a compound of formula (III-F): 18 Process for preparing a compound of formula (IF) by reacting with an F-fluorinating agent
[0243] [ka]
[0244] (In the formula,
[0245] [ka]
[0246] R 1F , R 2, X, n and LG are as defined herein above.
[0247] 18 Suitable solvents for F-fluorination include DMF, DMSO, acetonitrile, DMA, or mixtures thereof, preferably acetonitrile or DMSO. 18 Suitable agents for F-fluorination are K 18 F, Rb 18 F, Cs 18 F, Na 18 F, 18 F Tetra (C 1~6 (alkyl) ammonium salt, Kryptofix
[0222] 18 F and tetrabutylammonium [ 18 F] fluoride.
[0248] In one embodiment, the present invention provides a compound of formula (III-H): 3 A method for preparing a compound of formula (IH) by reacting with a H radiolabeling agent
[0249] [ka]
[0250] (In the formula,
[0251] [ka]
[0252] R 1 , R 2 , X, Z, p and m are as defined herein above.
[0253] 3 The H radiolabeling agent can be tritium gas. The method can be carried out in the presence of a catalyst such as palladium on carbon (Pd / C), a solvent such as dimethylformamide (DMF) and a base such as N,N-diisopropylethylamine (DIEA).
[0254] Alternatively, in another embodiment, the present invention relates to a method for preparing a compound of formula (IH) by radiolabeling a compound of formula (III-H) with a CT3 radiolabeling agent, wherein T is 3 H. CT3 radiolabeled agent is ICT3( 3 H derivative of iodomethane). The process may be carried out in the presence of a solvent such as dimethylformamide (DMF) and a base such as cesium carbonate or sodium hydride.
[0255] Radiopharmaceutical Preparations The compounds of the invention may also be used in kits for preparing radiopharmaceutical preparations. Due to radioactive decay, radiopharmaceuticals are usually prepared immediately before use. The kit typically includes a precursor of the compound of the invention and an agent that reacts with the precursor to introduce a radiolabel into the compound of the invention. The precursor of the compound of the invention may be, for example, a compound having formula (III-F) or (III-H). The agent may be a compound that is capable of carrying a radiolabel, e.g. 18 F or 3 It may be an agent that introduces H.
[0256] In one embodiment, part of the kit is a test kit for detecting and / or diagnosing a disease, disorder or abnormality associated with alpha-synuclein aggregates, the test kit comprising at least one precursor of a compound of the invention (e.g., a compound having formula (III-F) or (III-H)).
[0257] In another embodiment, part of the kit is a kit for preparing a radiopharmaceutical preparation, the kit comprising a sealed vial containing at least one precursor of a compound of the invention (e.g., a compound having formula (III-F) or (III-H)).
[0258] Diagnostic Compositions The compounds of the present invention are particularly suitable for imaging alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. With respect to alpha-synuclein protein, the compounds are particularly suitable for binding to alpha-synuclein aggregates, including but not limited to various types of Lewy bodies and / or Lewy neurites. The imaging can be performed in a mammal, preferably a human. The imaging is preferably in vitro imaging, ex vivo imaging or in vivo imaging. More preferably, the imaging is in vivo imaging; even more preferably, the imaging is preferably brain imaging. The imaging can also be eye / retina imaging. The compounds of the present invention are particularly suitable for use in diagnostic methods.
[0259] The diagnostic method may be performed on a mammal, preferably on a human. The tissue of interest on which the diagnostic method is performed may be the brain, tissue of the central nervous system (CNS), tissue of the eye (e.g., retinal tissue), peripheral organs, such as intestinal tissue or other tissue, or body fluids, such as cerebrospinal fluid (CSF) or blood. The tissue is preferably brain tissue.
[0260] In one embodiment, the present invention provides a diagnostic composition comprising a compound of the present invention and, optionally, at least one pharma- ceutically acceptable excipient, carrier, diluent and / or adjuvant.
[0261] Due to their design and binding properties, the compounds of the invention are suitable for use in the diagnosis of diseases, disorders and disorders associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. In another embodiment, diagnostic compositions comprising the compounds of the invention are also suitable for use in the diagnosis of diseases, disorders and disorders associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
[0262] In yet another embodiment, the compounds of the invention or diagnostic compositions comprising the compounds of the invention are suitable for use in imaging, such as in vitro imaging, ex vivo imaging or in vivo imaging, preferably the use is for in vivo imaging, more preferably the use is for brain imaging, particularly in humans.
[0263] In another embodiment, the compounds or diagnostic compositions of the present invention are particularly suitable for use in positron emission tomography imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
[0264] Diseases associated with alpha-synuclein aggregates are generally listed as synucleinopathies (or α-synucleinopathies). The compounds of the present invention are suitable for use in the diagnosis of diseases, disorders or disorders, including but not limited to Parkinson's disease (sporadic, familial with alpha-synuclein mutations, familial with mutations other than alpha-synuclein, pure autonomic failure and Lewy body dysphagia), SNCA duplication carriers, dementia with Lewy bodies ("pure" Lewy body dementia), Alzheimer's disease, sporadic Alzheimer's disease, familial Alzheimer's disease with APP mutations, familial Alzheimer's disease with PS-1, PS-2 or other mutations, familial British dementia, Lewy body variant of Alzheimer's disease and normal aging in Down's syndrome). Synucleinopathies involving neuronal and glial aggregates of alpha-synuclein include multiple system atrophy (MSA) (Shy-Drager syndrome, striatonigral degeneration and olivopontocerebellar atrophy).Other diseases that may have alpha-synuclein-immunoreactive lesions include traumatic brain injury, chronic traumatic encephalopathy, tauopathies (Pick's disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and Niemann-Pick disease type C1), motor neuron diseases, amyotrophic lateral sclerosis (sporadic, familial, and Guam ALS-dementia complex), neuroaxonal dystrophies, neurodegeneration type 1 with cerebral iron accumulation (Hallervorden-Spatz syndrome), prion diseases, ataxia-telangiectasia, Meige syndrome, subacute sclerosing panencephalitis, Gaucher disease, and other lysosomal storage diseases (including Kufor-Rakeb syndrome and Sanfilippo syndrome), and rapid eye movement (REM) sleep behavior disorder (Jellinger, Mov Disord 2003, 18 Suppl. 6, S2-12; Galvin et al., JAMA Neurology 2001, 58(2), pp. 186-190;Kovari et al., Acta Neuropathol. 2007, 114(3), pp. 295-8;Saito et al., J Neuropathol Exp Neurol. 2004, 63(4), pp. 323-328;McKee et al., Brain, 2013, 136(Pt1), pp. 43-64;Puschmann et al., Parkinsonism Relat Disord 2012, 18S1, S24-S27;Usenovic et al., J Neurosci. 2012, 32(12), pp. 4240-4246;Winder-Rhodes et al., Mov Disord. 2012, 27(2), pp. 312-315;Ferman et al., J Int Neuropsychol Soc. 2002, 8(7), pp. 907-914). Preferably, the compounds of the present invention are suitable for use in the diagnosis of Parkinson's disease, multiple system atrophy, dementia with Lewy bodies, Parkinson's disease dementia, SNCA duplication carriers or Alzheimer's disease, more preferably Parkinson's disease (PD).
[0265] In a method of diagnosing a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites (e.g., Parkinson's disease), or a predisposition thereto, in a subject, the method comprises: (a) administering to a subject a diagnostically effective amount of a compound of the invention, or a diagnostic composition comprising a compound of the invention; (b) distributing the compound of the invention to a target tissue (e.g., brain tissue, tissue of the central nervous system (CNS), eye tissue, tissue of a peripheral organ or other tissue) or to a body fluid (e.g., cerebrospinal fluid (CSF) or blood); and (c) imaging the tissue or fluid of interest. Includes.
[0266] If the amount of compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, is increased compared to normal control levels, the subject is suffering from or at risk of developing a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites.
[0267] The compounds of the present invention can be used to image alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in any sample of a patient or in a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The compounds can cross the blood-brain barrier. As a result, they are particularly suitable for imaging alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the brain, tissues of the central nervous system (CNS), tissues of the eye (e.g., retinal tissue), peripheral organs, such as intestinal tissue or other tissues, or body fluids, such as cerebrospinal fluid (CSF) or blood.
[0268] For diagnostic applications, the compounds of the invention are preferably administered in the form of a diagnostic composition comprising the compounds of the invention. A "diagnostic composition" is defined herein as a composition comprising one or more compounds of the invention in a form suitable for administration to a patient, such as a mammal, e.g., a human, and suitable for use in diagnosing a particular disease, disorder or abnormality in a tissue. Preferably, the diagnostic composition further comprises a pharma- ceutically acceptable excipient, carrier, diluent or adjuvant. Administration is preferably performed by injecting the composition, more preferably as an aqueous solution, as defined below. Such compositions may optionally contain further ingredients, such as a buffer; a pharma-ceutically acceptable solubilizer (e.g., cyclodextrin or a surfactant, e.g., Pluronic, Tween or phospholipid); and a pharma-ceutically acceptable stabilizer or antioxidant (e.g., ascorbic acid, gentisic acid or para-aminobenzoic acid). The dose of the compounds of the invention varies depending on the exact compound administered, the mass of the patient, and other variables apparent to a practitioner in the art.
[0269] While it is possible for the compounds of the invention to be administered alone, it is preferable to formulate them into diagnostic compositions according to standard pharmaceutical practice.Thus, the invention also provides diagnostic compositions comprising a diagnostically effective amount of a compound of the invention, optionally in admixture with at least one pharma-ceutically acceptable excipient, carrier, diluent or adjuvant.
[0270] Pharmaceutically acceptable excipients are well known in the pharmaceutical industry and are described, for example, in Remington's Pharmaceutical Sciences, 15th ed., Mack Publishing Co., New Jersey (1975). Pharmaceutical excipients can be selected for the intended route of administration and standard pharmaceutical practice. An excipient must be acceptable in the sense of not being harmful to the recipient thereof.
[0271] Pharmaceutically useful excipients, carriers, adjuvants and diluents that can be used to formulate the diagnostic compositions of the present invention may include, for example, solvents, such as monohydric alcohols, e.g., ethanol, isopropanol, and polyhydric alcohols, e.g., glycols, and edible oils, e.g., soybean oil, coconut oil, olive oil, safflower oil, cottonseed oil, oily esters, e.g., ethyl oleate, isopropyl myristate, binders, adjuvants, solubilizers, thickeners, stabilizers, disintegrants, glidants, lubricants, buffers, emulsifiers, wetting agents, suspending agents, sweeteners, colorants, flavorings, coating agents, preservatives, antioxidants, processing agents, drug delivery modifiers and enhancers, e.g., calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methylcellulose, sodium carboxymethylcellulose, dextrose, hydroxypropyl-β-cyclodextrin, polyvinylpyrrolidone, low melting point waxes, and ion exchange resins.
[0272] The route for administration (delivery) of the compound of the present invention includes, but is not limited to, one or more of intravenous, gastrointestinal, intrathecal, intraperitoneal, intramuscular, oral (e.g., as a tablet, capsule, or as an ingestible liquid), topical, mucosal (e.g., as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g., by an injectable form), intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intraventricular, intracerebral, subcutaneous, ocular (including intravitreal or intracameral), transdermal, rectal, buccal, epidural, and sublingual.Preferably, the route for administration (delivery) of the compound of the present invention is intravenous.
[0273] For example, the compounds may be administered orally in the form of tablets, capsules, ovoids, elixirs, solutions or suspensions, which may contain flavorings or colorants for immediate, delayed, modified, sustained, pulsed or controlled release applications.
[0274] Tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium hydrogen phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. In addition, lubricants may be included such as magnesium stearate, stearic acid, glyceryl behenate and talc. Similar types of solid compositions may also be used as fillers in gelatin capsules. Preferred excipients in this context include starch, cellulose, milk sugar (lactose) or high molecular weight polyethylene glycols. In aqueous suspensions and / or elixirs, the drug may be combined with various sweetening or flavoring agents, coloring agents or pigments, emulsifying and / or suspending agents, and diluents such as water, ethanol, propylene glycol, and glycerin, and combinations thereof.
[0275] Preferably, in diagnostic applications, the compounds of the present invention are administered parenterally. When the compounds of the present invention are administered parenterally, examples of such administration include one or more of intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular or subcutaneous administration of the compound, and / or administration by using injection techniques. For parenteral administration, the compound is best used in the form of a sterile aqueous solution, which may contain other substances, for example, sufficient salts or glucose to make the solution isotonic with blood. The aqueous solution should be suitably buffered (preferably to a pH of 3 to 9) if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
[0276] As indicated, the compounds of the present invention can be administered intranasally or by inhalation, conveniently delivered in the form of a dry powder inhaler or in the form of an aerosol spray from a pressurized container, pump, spray or nebulizer with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, hydrofluoroalkanes, such as 1,1,1,2-tetrafluoroethane (HFA134AT) or 1,1,1,2,3,3,3-heptafluoropropane (HFA227EA), carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve that delivers a metered amount. The pressurized container, pump, spray or nebulizer can contain a solution or suspension of the active compound, for example using a mixture of ethanol as a solvent and a propellant, which can further contain a lubricant, such as sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound and a suitable powder base such as lactose or starch.
[0277] Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or powder.The compounds of the invention may also be administered dermally or transdermally, for example, by the use of a skin patch.
[0278] They can also be administered by pulmonary or rectal routes. They can also be administered by ocular routes. For ophthalmic use, the compounds can be formulated as micronized suspensions in isotonic, pH-adjusted, sterile saline, or preferably as solutions in isotonic, pH-adjusted, sterile saline, optionally in combination with preservatives, such as benzalkonium chloride. Alternatively, they can be formulated in ointments, such as petrolatum.
[0279] For topical application to the skin, the compounds of the invention may be formulated in a suitable ointment containing the active compound suspended or dissolved in a mixture of one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax, and water, or they may be formulated in a suitable lotion or cream containing the active compound suspended or dissolved in a mixture of one or more of the following: mineral oil, sorbitan monostearate, polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.
[0280] Typically, a physician will determine the actual dosage that will be most suitable for an individual subject. The specific dose level and frequency of administration for any particular individual may vary and will depend on a variety of factors, including the activity of the particular compound employed, the metabolic stability and length of action of that compound, age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the precise severity of the condition and the individual diagnosis.
[0281] The diagnostic compositions of the invention can be produced in a manner known per se to those skilled in the art, for example as described in Remington's Pharmaceutical Sciences, 15th Edition, Mack Publishing Co., New Jersey (1975).
[0282] The compounds of the present invention are useful as in vitro analytical standards or in vitro screening tools. They are also useful in in vivo diagnostic methods.
[0283] The compound according to the present invention can also be provided in the form of a mixture, a pharmaceutical composition, or a combination comprising the compound according to the present invention and at least one compound selected from an imaging agent different from the compound according to the present invention, a pharma- ceutically acceptable excipient, carrier, diluent, or adjuvant.The imaging agent different from the compound according to the present invention is preferably present in a diagnostically effective amount.More preferably, the imaging agent different from the compound according to the present invention is an Abeta or tau imaging agent.
[0284] method In one embodiment, the invention provides a method of diagnosing a disease, disorder or abnormality associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a subject, comprising: (a) administering to a subject a compound of the invention, or a diagnostic composition comprising a compound of the invention; (b) binding the compound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites; and (c) detecting compounds that bind to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites. The present invention provides a method comprising:
[0285] Optionally, the method further comprises: (d) generating an image representative of the location and / or amount of compound bound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites. It may further include.
[0286] In another embodiment, the invention provides a method of positron emission tomography (PET) imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject, comprising: (a) administering to a subject a compound of the invention, or a diagnostic composition comprising a compound of the invention; (b) binding the compound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites; and (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, by acquiring positron emission tomography (PET) images of the subject's tissue. The present invention provides a method comprising:
[0287] In another embodiment, the invention provides a method (e.g., an in vivo or in vitro method) for detecting and optionally quantifying alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject, comprising: (a) contacting a sample or a particular body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of the invention or a diagnostic composition comprising a compound of the invention; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally quantifying the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The present invention relates to a method comprising the steps of:
[0288] In one embodiment, the present invention provides a method of collecting data for diagnosing a disease, disorder, or abnormality associated with alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample or a specific body part or area suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to the invention or a diagnostic composition comprising a compound according to the invention; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region. This refers to a method including:
[0289] If the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, is greater than the normal control value, it can be inferred that the patient is suffering from a disease, disorder or abnormality associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
[0290] Yet another embodiment of the present invention is a method of collecting data to determine a predisposition to a disease, disorder, or condition associated with alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample or a specific body part or area suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to the invention or a diagnostic composition comprising a compound according to the invention; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region. This refers to a method including:
[0291] If the amount of compound that binds to alpha-synuclein aggregates is greater than the normal control value of a healthy / reference subject, this indicates that the patient is suffering from or at risk of developing a disease, disorder or abnormality associated with alpha-synuclein aggregates. In particular, if the amount of compound that binds to alpha-synuclein aggregates is greater than that expected in a person who does not show clinical evidence of a disease, disorder or abnormality associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, the patient can be presumed to have a predisposition to a disease, disorder or abnormality associated with alpha-synuclein aggregates.
[0292] In a further aspect, the invention provides a method of collecting data for prognosing a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample, a particular body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to the invention, or a diagnostic composition comprising a compound according to the invention; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The present invention relates to a method comprising the steps of:
[0293] The likelihood (e.g., likelihood, duration, and / or extent) of progression and / or recovery from the disease, disorder or disorder can be estimated by a medical professional based on the presence or absence of a compound that binds to alpha-synuclein aggregates, the amount of compound that binds to alpha-synuclein aggregates, etc. If necessary, steps (a) through (c), and optional step (d), if present, can be repeated over time to monitor the progression of the disease, disorder or disorder, and thus make the estimation more reliable.
[0294] A further aspect is a method of collecting data to monitor the progression (or evolution) of a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a patient, comprising: (a) contacting a sample, a particular body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to the invention, or a diagnostic composition comprising a compound according to the invention. (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The present invention relates to a method comprising:
[0295] In methods for monitoring progression, the amount of compound that binds to alpha-synuclein aggregates can optionally be compared at various time points during treatment, for example before and after initiation of treatment, or at various time points after initiation of treatment.
[0296] Typically, the patient is or has been treated for a disease, disorder or condition associated with alpha-synuclein aggregates, or is / has been treated for a synucleinopathy. In particular, the treatment may involve the administration of a medicament suitable for the treatment of a disease, disorder or condition associated with alpha-synuclein aggregates.
[0297] In another embodiment, the invention provides a method of collecting data to predict responsiveness to treatment with a pharmaceutical agent in a patient suffering from a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample, a particular body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of the invention, or a diagnostic composition comprising a compound of the invention; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The present invention relates to a method comprising the steps of:
[0298] In a method for predicting reactivity, the method includes, prior to step (a), steps (i) to (vi): (i) contacting a sample or a particular body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound of the invention that specifically binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (ii) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (iii) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (iv) correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; (v) optionally comparing the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a normal control value; and (vi) treating the patient with a medicament It may further include.
[0299] Optionally, the method further comprises, after step (d) or step (e), step (A): (A) comparing the amount of compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, determined in step (iv), with the amount of compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, determined in step (d). It may further include.
[0300] In methods for predicting responsiveness, the amount of compound / protein aggregate complex can optionally be compared at various time points during treatment, such as before and after initiation of treatment, or at various time points after initiation of treatment. A change, particularly a decrease, in the amount of compound / protein aggregate complex can indicate that the patient is likely to be responsive to the respective treatment.
[0301] If the amount of compound that binds to alpha-synuclein aggregates decreases over time, the patient can be presumed to be responsive to the treatment. If the amount of compound that binds to alpha-synuclein aggregates remains essentially constant or increases over time, the patient can be presumed to be non-responsive to the treatment.
[0302] Alternatively, responsiveness can be estimated by determining the amount of compound that binds to alpha-synuclein aggregates. The amount of compound that binds to alpha-synuclein aggregates can be compared to a control value, such as a normal control value, a preclinical control value, or a clinical control value. Alternatively, the control value can refer to a control value of a subject known to be responsive to a treatment, or the control value can refer to a control value of a subject known to be non-responsive to a treatment. The outcome for responsiveness can be "responsive" to a treatment, "non-responsive" to a treatment, or "unknown response" to a treatment. Response to treatment can be different for each patient.
[0303] Optionally, the diagnostic compositions can be used to visualize alpha-synuclein aggregates before, during and after surgical procedures (e.g., deep brain stimulation (DBS)) and non-invasive brain stimulation (e.g., repetitive transcranial magnetic stimulation (rTMS)). Surgical techniques, including DBS, in addition to currently used optimal medical treatments, improve advanced symptoms of PD. Over the past two decades, rTMS has been closely examined as a possible treatment for PD (Ying-hui Chou et al., JAMA Neurol. 2015 Apr. 1;72(4):432-440).
[0304] In any of the above methods, optionally, the step of correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region, comprises: - determining the amount of the compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; - correlating the amount of the compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the amount of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and - optionally comparing the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region with a normal control value in a healthy control subject. Includes.
[0305] The control value can be, for example, a normal control value, a preclinical control value and / or a clinical control value.
[0306] A "healthy control subject" or "healthy volunteer (HV) subject" is one who does not exhibit clinical evidence of a disease, disorder or abnormality associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
[0307] If the amount of compound that binds to alpha-synuclein aggregates in any of the methods summarized above is greater than the normal control value, the patient may be predicted to be suffering from or susceptible to developing a disease, disorder or condition associated with alpha-synuclein aggregates or a synucleinopathy.
[0308] A sample or a particular body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, is contacted with a compound of the invention.
[0309] Any of the compounds of the invention may be used in the methods summarized above. Preferably, detectably labeled compounds of the invention are used in the methods summarized above.
[0310] The particular body part or region includes the whole or partial body area or body part of a patient suspected of containing alpha-synuclein aggregates, preferably of a mammal, more preferably of a human. The particular body part or region may be the brain, the central nervous system, the eye or a peripheral organ, such as the intestine, preferably the brain.
[0311] The tissue may be brain tissue, tissue of the central nervous system (CNS), tissue of the eye (e.g. retinal tissue), peripheral organs such as intestinal tissue or other tissue, or body fluids such as cerebrospinal fluid (CSF) or blood. The tissue is preferably brain tissue. Preferably, the sample is an in vitro sample from a patient.
[0312] In the above methods, the compounds of the invention can be contacted with a sample or a particular body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, by any suitable method.
[0313] In in vitro methods, the compound of the invention and the liquid sample may simply be mixed.
[0314] In the in vivo method, a particular body part or area can be contacted with a compound of the invention by administering to a patient an effective amount of a compound of the invention.
[0315] The effective amount of the compound of the present invention is an amount suitable for determining the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a sample, a specific body part or body region using a selected analytical technique. The amount is not particularly limited and depends on the compound of formula (I), the type of detectable label, the sensitivity of each analytical method, and each device. The amount can be appropriately selected by those skilled in the art.
[0316] The compound is then allowed to bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. Allowing the compound to bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, includes allowing a sufficient amount of time for the compound of the present invention to bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The amount of time required for binding depends on the type of test (e.g., in vitro or in vivo) and can be determined by the skilled artisan through routine experimentation. For in vivo methods, the amount of time depends on the time required for the compound to reach a particular body part or area suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The amount of time should not be extended excessively to avoid washout and / or metabolism of the compound of the present invention.
[0317] Compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, can then be detected by any suitable method. Methods for detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, are not particularly limited and depend, among other things, on the detectable label, the type of sample, the specific body part or body region, and whether the method is an in vitro or in vivo method. Examples of possible methods include, but are not limited to, fluorescent imaging techniques or nuclear imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) and contrast magnetic resonance imaging (MRI). These have been described and allow visualization of alpha-synuclein biomarkers. Fluorescent imaging techniques and / or nuclear imaging techniques can be used to monitor and / or visualize the distribution of detectably labeled compounds within a sample or a specific body part or body region. The imaging system obtains an image of the bound detectable label, e.g., a radioisotope, particularly a positron emitter or a gamma emitter, present in the sample being tested, the particular body part being tested, or the body region being tested. Preferably, compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, are detected by an imaging device, e.g., a PET or SPECT scanner, more preferably a PET.
[0318] The amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, may also be determined by visual or quantitative analysis, for example using PET scan images.
[0319] The compounds according to the invention, or precursors thereof, may also be incorporated into a test kit for detecting alpha-synuclein protein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The test kit typically includes a container holding one or more compounds according to the invention, or precursors thereof, and instructions for use of the compound to bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, and to detect the formation of compounds that bind to alpha-synuclein aggregates, thereby correlating the presence or absence of compounds that bind to alpha-synuclein aggregates with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
[0320] The term "test kit" generally refers to any diagnostic kit known in the art. More specifically, the term any diagnostic kit refers to the diagnostic kit described in Zrein et al., Clin. Diagn. Lab. Immunol., 1998, 5, 45-49.
[0321] The detectably labeled compounds of the present invention, preferably 18 a compound of formula (IF) labelled with F, or 3 The formula (IH * The dose of the compound of (IH) or (IH) will vary depending on the exact compound to be administered, the patient's weight, the size and type of the sample, and other variables evident to a practitioner of ordinary skill in the art. In general, the dose may be preferably in the range of 0.001 μg / kg to 10 μg / kg, preferably 0.01 μg / kg to 1.0 μg / kg. The radioactive dose may be, for example, 100 to 600 MBq, more preferably 150 to 450 MBq.
[0322] Methods of Synthesizing the Compounds of the Invention The compounds of the present invention may be prepared according to the definition of the compound of formula (I) by the routes described in the following schemes or examples. All methods described herein may be carried out in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "for example") provided herein is intended merely to better elucidate the invention and does not impose limitations on the scope of the invention unless otherwise claimed. In the following general methods, R 1 , R 2 ,
[0323] [ka]
[0324] , X, LG and n are as previously defined in the above embodiments or are limited to the meaning in the schemes. Unless otherwise specified, starting materials are commercially available or prepared by known synthetic methods.
[0325] General synthetic scheme for preparing compounds and precursors of the present invention:
[0326] [ka]
[0327] Commercially available hydrazines can be condensed with appropriate ketones to give the corresponding hydrazones. The crude hydrazones can be subjected to cyclization using POCl3 / DMF to give intermediate A. Reductive amination with an amine in the presence of a reducing agent gives intermediate B. Saponification reaction can be carried out under basic or acidic conditions to give intermediate C. Ring closure can then be carried out using standard conditions, for example, HATU or POCl3 or NMI / TCFH in a suitable solvent. Finally, intermediate D can be further functionalized using an SNAr reaction to give compounds of formula (I).
[0328] [ka]
[0329] R 2 Groups can be introduced to the protected pyrrolone using metal coupling, such as an Ullmann reaction. Intermediate E can be deprotected using acidic conditions. Oxime formation, using, for example, a nitrite source under acidic conditions, can then deliver intermediate G. Hydrazone formation can be carried out using intermediate G and commercially available hydrazine, followed by cyclization by activating the hydroxyl of the oxime, using, for example, acetic anhydride, to deliver intermediate I. Finally, intermediate I can be further functionalized using an SNAr reaction to give compounds of formula (I).
[0330] The present invention 18 General synthesis of F-labeled compounds 18 The compound having formula (I) labeled with F can be prepared by reacting a precursor compound with LG, 18 F, as described below. 18 It can be prepared by reacting with an F-fluorinating agent.
[0331] 18 Reagents, solvents and conditions that can be used for F-fluorination are well known to those skilled in the art (L. Cai, S. Lu, V. Pike, Eur. J. Org. Chem 2008, pp. 2853-2873; J. Fluorine Chem., 27(1985):pp. 177-191; Coenen, Fluorine-18 Labeling Methods: Features and Possibilities of Basic Reactions, (2006), Schubiger PA, Friebe M., Lehmann L. (eds.), PET-Chemistry - The Driving Force in Molecular Imaging. Springer, Berlin Heidelberg, pp. 15-50). Preferably,18 The solvent used for F-fluorination is DMF, DMSO, acetonitrile, DMA or a mixture thereof, preferably the solvent is acetonitrile or DMSO.
[0332] Any suitable 18 F-fluorinating agents may be used. Typical examples are H 18 F, Alkaline or alkaline earth 18 F-fluoride (e.g., K 18 F, Rb 18 F, Cs 18 F and Na 18 F). Optionally, 18 The F-fluorinating agent may be used in combination with a chelating agent, such as a cryptand (e.g.: 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane, Kryptofix®) or a crown ether (e.g.: 18-crown-6). Alternatively, 18 F-fluorinating agent is 18 A tetraalkylammonium salt of F or 18 Tetraalkylphosphonium salts of F, such as 18 F Tetra (C 1~6 (alkyl) ammonium salt or 18 F Tetra (C 1~6 The alkyl group may be a phosphonium salt. 18 F-fluorinating agent is K 18 F, H 18 F, Cs 18 F, Na 18 F, 18 F Tetra (C 1~6 (alkyl) ammonium salt, kryptofix
[0222] 18 F or tetrabutylammonium [ 18 F] fluoride.
[0333] As a radioactive label 18 Although the reaction for F is shown above, other radiolabels may be introduced following a similar procedure.
[0334] This invention is illustrated by the following examples which should not be construed as limiting. EXAMPLES
[0335] Exemplification of the Invention The compounds of the present disclosure can be prepared by methods of organic synthesis known in the art. It is understood that in all of the methods, protective groups for sensitive or reactive groups can be used where necessary, in accordance with general principles of chemistry. Protective groups are manipulated according to standard methods of organic synthesis (TW Green and PGM Wuts (2014) Protective Groups in Organic Synthesis, 5th Edition, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
[0336] Unless otherwise noted, all reagents and solvents were obtained from commercial sources and used without further purification.
[0337] Chemical names were generated using CambridgeSoft's ChemBioDraw Ultra v20.
[0338] Temperatures are given in degrees Celsius. Unless otherwise noted, all evaporations are carried out under reduced pressure, typically at about 15 mm Hg to 100 mm Hg (=20-133 mbar). The structures of final products, intermediates and starting materials were confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR.
[0339] Abbreviation The abbreviations used are conventional in the art.
[0340] [Table 1]
[0341] Analytical details, preparation and analytical methods NMR measurements were performed on a DRX-400 MHz NMR spectrometer, a Bruker AV-400 MHz NMR spectrometer, or a Spinsolve 80 MHz NMR spectrometer in deuterated solvents with or without tetramethylsilane (TMS) as an internal standard. Chemical shifts (o) are reported in ppm downfield from TMS, and spectral splitting patterns are designated as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), septet (sept), multiplet, unresolved or overlapping signals (m) or broad signals (br). Deuterated solvents are indicated in parentheses with chemical shifts of dimethylsulfoxide (δ 2.50 ppm), methanol (δ 3.31 ppm), chloroform (δ 7.26 ppm), or other solvents indicated in the NMR spectral data.
[0342] Mass spectra (MS) were recorded on a Waters Advion CMS mass spectrometer or a UPLC H-Class Plus equipped with a photodiode array detector, and a Qda mass spectrometer.
[0343] Column chromatography was performed using silica gel (Fluka: silica gel 60, 0.063-0.2 mm) and suitable solvents as indicated in the specific examples.
[0344] Flash column chromatography system: Flash purification was performed using a Biotage Isolera One flash purification system using HP-Sil or KP-NH SNAP cartridges (Biotage) and solvent gradients as indicated in the examples.
[0345] Thin layer chromatography (TLC) was performed on silica gel plates with UV detection.
[0346] Preparation Example (Preparation Example 1)
[0347] [ka]
[0348] Step 1: A stirred solution of 2-bromo-5-hydrazinylpyridine (10 g, 0.053 mol) in ethanol (100 ml) was cooled to 0° C. and a solution of commercially available methyl 2-oxopropanoate (6.24 g, 0.062 mol) in ethanol (25 ml) was added dropwise over 15 min at 0° C. After the mixture was stirred at room temperature for 3 h, it was evaporated to give 14.4 g of product (92% by LCMS), LC / MS [M+H] 273.0.
[0349] Step 2: Vilsmeier-Haack reagent was prepared in a round bottom flask under ice-cooled condition (0-5°C) by adding 11 mL (0.13 mol) of POCl3 to 55 mL of DMF (0.7 mol) at 0°C under constant stirring. Methyl 2-(2-(6-bromopyridin-3-yl)hydrazono)propanoate (11.3 g, 0.041 mol) from step 1 in 25 mL of DMF was added to the Vilsmeier-Haack reagent and stirred for 1 h, after which the reaction mixture was kept at 70°C on a water bath for 4 h. After reaction, the mixture was poured into crushed ice under constant manual stirring. After neutralization with K2CO3 solution, ethyl acetate was added. The organic phase was separated and the aqueous phase was extracted with EtOAc. The combined organic solution was washed with water (100 mL) and brine (100 mL), dried and concentrated. The product was purified by recrystallization from ethanol (10 g, 95% purity), LC / MS [M+H] 266.0.
[0350] Step 3: A suspension of pyridin-3-amine (0.18 g, 0.0019 mol) in MeOH (80 mL) was treated with methyl 1-(6-chloropyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate (0.5 g, 0.0019 mol) from step 2, and the resulting mixture was heated to reflux for 4 h. The mixture was cooled to room temperature, and NaBH4 (0.078 g, 0.0021 mmol) was added in portions. The reaction mixture was stirred at room temperature overnight. The mixture's solvent was then evaporated, and water and AcOH were added. The resulting mixture was extracted three times with CH2Cl2, dried over MgSO4, and the solvent was removed in vacuo to give the crude product (0.5 g), which was used in the next step without purification. LC / MS [M+H] 344.0.
[0351] Step 4: Methyl 1-(6-chloropyridin-3-yl)-4-((pyridin-3-ylamino)methyl)-1H-pyrazole-3-carboxylate (0.3 g, 0.00087 mol) from step 3 was dissolved in THF, 1 mL of an aqueous solution of KOH (0.098 g, 0.00175 mol) was added at room temperature, and the mixture was stirred overnight. The solvent was evaporated and 1.5 ml of water was added. Acid was added to the reaction solution to adjust the pH to 6.0. The solvent was evaporated to give 0.28 g of the product as the HCl salt. LC / MS [M+H] 330.2.
[0352] Step 5: To a suspension of 1-(6-chloropyridin-3-yl)-4-((pyridin-3-ylamino)methyl)-1H-pyrazole-3-carboxylic acid (0.1 mg, 0.0003 mol) from step 4 in pyridine (volume: 2 ml) was added phosphoryl trichloride (0.46 g, 0.38 ml, 0.003 mol) at -10°C, the mixture was stirred at -10°C for 10 min, the reaction mixture was then stirred at room temperature for 16 h. The reaction mixture was slowly quenched with water, a saturated solution of NaHCO3 was added and the aqueous phase was extracted three times with a solution of DCM / MeOH (9:1). The organic phase was dried over Na2SO4 and the solvent was evaporated to give the crude product (0.13 g), LC / MS [M+H] 312.0.
[0353] (Preparation Example 2)
[0354] [ka]
[0355] Step 1: Methyl 1-(6-chloropyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate (2.0 g, 7.53 mmol) was dissolved in MeOH (50 ml) and 1-methyl-1H-pyrazol-4-amine (731.25 mg, 7.53 mmol), acetic acid (474.77 mg, 7.91 mmol, 460.0 μl, 1.05 eq.) were added. The mixture was stirred at 60° C. for 18 h, then cooled to 0° C. and sodium cyanoborohydride (946.33 mg, 15.06 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was poured into aqueous Na2CO3 and extracted twice with DCM (50 mL). The combined organic layers were washed with brine and concentrated in vacuo to give methyl 1-(6-chloropyridin-3-yl)-4-[(1-methyl-1H-pyrazol-4-yl)amino]methyl-1H-pyrazole-3-carboxylate (2.2 g, 6.34 mmol, 84.3% yield). LC / MS [M+H] 347.2.
[0356] Step 2: Methyl 1-(6-chloropyridin-3-yl)-4-[(1-methyl-1H-pyrazol-4-yl)amino]methyl-1H-pyrazole-3-carboxylate from step 1 (2.2 g, 6.34 mmol) was dissolved in 10 M HCl (50 ml), stirred at 100° C. for 4 h, and concentrated in vacuo to give 1-(6-chloropyridin-3-yl)-4-[(1-methyl-1H-pyrazol-4-yl)amino]methyl-1H-pyrazole-3-carboxylic acid (2.2 g, 92.0% purity, 6.08 mmol, 95.9% yield). LC / MS [M+H] 333.0
[0357] Step 3: 1-(6-chloropyridin-3-yl)-4-[(1-methyl-1H-pyrazol-4-yl)amino]methyl-1H-pyrazole-3-carboxylic acid (1.5 g, 4.51 mmol) from step 2 and 1-methyl-1H-imidazole (1.67 g, 20.32 mmol, 1.62 ml, 4.5 eq.) were dissolved in DMF (10 mL) and chloro-N,N,N,N-tetramethylformamidinium hexafluorophosphate (1.52 g, 5.42 mmol) was added in one portion. The reaction mixture was stirred overnight. The precipitate formed was filtered off and dried to give 2-(6-chloropyridin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-6-one (200.0 mg, 635.47 μmol, 14.1% yield). LC / MS [M+H] 315.2.
[0358] (Preparation Example 3)
[0359] [ka]
[0360] Step 1: Methyl 1-(6-chloropyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate (2.19 g, 8.25 mmol) was dissolved in MeOH (50 ml) and 5-methoxypyridin-3-amine (1.02 g, 8.25 mmol), acetic acid (520.0 mg, 8.66 mmol, 500.0 μl, 1.05 eq.) were added. The mixture was stirred at 60° C. for 18 h, then cooled to 0° C. and sodium cyanoborohydride (1.04 g, 16.5 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was poured into aqueous Na2CO3 and extracted twice with DCM (50 ml). The combined organic layers were washed with brine and concentrated in vacuo to give methyl 1-(6-chloropyridin-3-yl)-4-[(5-methoxypyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylate (2.3 g, 95.0% purity, 5.85 mmol, 70.9% yield). LC / MS [M+H] 374.0.
[0361] Step 2: Methyl 1-(6-chloropyridin-3-yl)-4-[(5-methoxypyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylate from step 1 (2.1 g, 5.62 mmol) was dissolved in 10 M HCl (50 ml), stirred at 100° C. for 4 h, and concentrated in vacuo to give 1-(6-chloropyridin-3-yl)-4-[(5-methoxypyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylic acid (2.2 g, 80.0% purity, 4.89 mmol, 87.1% yield), which was used in the next step without further purification. LC / MS [M+H] 374.0.
[0362] Step 3: Phosphoryl trichloride (12.35 g, 80.57 mmol, 7.51 ml, 10.0 equiv) was cooled to -15°C and added to 1-(6-chloropyridin-3-yl)-4-[(5-methoxypyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylic acid (2.9 g, 8.06 mmol) from step 2. The resulting mixture was stirred at room temperature overnight. The reaction mixture was added to ice water, quenched with K2CO3, and extracted twice with CH3Cl / MeOH (4 / 1). The combined organic layers were concentrated under vacuum. The crude product was purified by flash chromatography (Interchim, 40 g SiO2, CHCl3 / MeCN / methanol, 50% MeCN to 18% methanol, flow rate = 40 mL / min) to give 2-(6-chloropyridin-3-yl)-5-(5-methoxypyridin-3-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-6-one (180.0 mg, 97.5% purity, 513.53 μmol, 6.4% yield), LC / MS [M+H] 374.0.
[0363] (Preparation Example 4)
[0364] [ka]
[0365] Step 1: To a solution of methyl 1-(6-chloropyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate (2.19 g, 8.25 mmol) in MeOH (50 mL) was added 6-methylpyridin-3-amine (891.92 mg, 8.25 mmol) and acetic acid (520.0 mg, 8.66 mmol, 500.0 μl, 1.05 equiv). The mixture was stirred at 60° C. for 18 h, then cooled to 0° C. and sodium cyanoborohydride (1.04 g, 16.5 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was poured into a saturated aqueous solution of Na2CO3 and extracted twice with DCM (50 mL). The combined organic layers were washed with brine and concentrated in vacuo to give methyl 1-(6-chloropyridin-3-yl)-4-[(6-methylpyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylate (2.5 g, 90.0% purity, 6.29 mmol, 76.2% yield). LC / MS [M+H] 358.0.
[0366] Step 2: Methyl 1-(6-chloropyridin-3-yl)-4-[(6-methylpyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylate from step 1 (2.3 g, 6.43 mmol) was dissolved in HCl (10 M, 50 mL) and stirred at 100° C. for 4 h, then concentrated in vacuo to give 1-(6-chloropyridin-3-yl)-4-[(6-methylpyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylic acid (2.3 g, 91.0% purity, 6.09 mmol, 94.7% yield). LC / MS [M+H] 344.0.
[0367] Step 3: Phosphoryl trichloride (9.82 g, 64.05 mmol, 5.97 ml, 10.0 eq.) was cooled to -15°C and added to 1-(6-chloropyridin-3-yl)-4-[(6-methylpyridin-3-yl)amino]methyl-1H-pyrazole-3-carboxylic acid (2.2 g, 6.4 mmol) from step 2. The resulting mixture was stirred at room temperature overnight. The reaction mixture was added to ice water, quenched with K2CO3, and extracted twice with CH3Cl / MeOH (4 / 1). The combined organic layers were concentrated under vacuum to give the crude product, which was purified by flash chromatography (Interchim, 40 g SiO2, CHCl3 / MeCN / methanol, 50% MeCN to 18% methanol, flow rate = 40 mL / min, 11 min at room temperature) to give 2-(6-chloropyridin-3-yl)-5-(6-methylpyridin-3-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-6-one (200.0 mg, 90.0% purity, 552.57 μmol, 8.6% yield), LC / MS [M+H] 326.0.
[0368] (Preparation Example 5)
[0369] [ka]
[0370] Step 1: 4-Methoxy-1H-pyrrol-2(5H)-one (1 g, 8.84 mmol), 3-iodopyridine (3.625 g, 17.68 mmol), K2CO3 (2.44 g, 17.68 mmol) and CuI (673 mg, 3.536 mmol) were mixed in 35 ml of dry dioxane. Tetramethylethylenediamine (TMEDA) (410 mg, 3.536 mmol) and proline (407 mg, 3.536 mmol) were then added in one portion. The reaction mixture was sealed and heated at 110° C. with shaking for 48 h. The mixture was cooled and the solvent was evaporated under high vacuum. The residue was dissolved in H2O, extracted twice with EtOAc, washed with brine and evaporated to give the crude product (1.2 g, 92% by LCMS). LC / MS [M+H] 191.2.
[0371] Step 2: 4-Methoxy-1-(pyridin-3-yl)-1H-pyrrol-2(5H)-one from step 1 (1 g, 5.25 mmol) and 37% HCl (1 ml, 10.5 mmol, 2 eq.) were mixed in toluene (52.5 ml). The reaction mixture was heated at 50° C. for 2 h. The mixture was then cooled and the solvent was evaporated under high vacuum to give the crude product, which was used in the next step without further purification (0.9 g, 87% pure by LCMS), LC / MS [M+H] 177.2.
[0372] Step 3: To 1.5 M aqueous sulfuric acid (0.83 ml, 1.245 mmol) was added dropwise a solution of 4-hydroxy-1-(pyridin-3-yl)-1H-pyrrol-2(5H)-one (155.73 mg, 0.884 mmol) from step 2, sodium nitrite (95.0 mg, 1.336 mmol) and 1.0 M aqueous sodium hydroxide (0.96 ml, 0.960 mmol) in THF (7.0 ml) at 0° C. The mixture was stirred for 30 min at 0° C. and added to a solution of 2-bromo-5-hydrazinylpyridine (166.2 mg, 0.884 mmol) and NaHCO3 (75 mg, 1 eq.) in water (2.4 ml) / THF (7.5 ml) and the mixture was stirred at room temperature for 12 h. At this time, water (10 ml) was added and the resulting heterogeneous mixture was filtered. The collected solid was washed with water and dissolved in DCM. The DCM solution was dried (Na2SO4) and evaporated to give a brown solid (170 mg, 92%, LCMS). LC / MS [M+H] 376.0 1 H NMR (400 MHz, DMSO-d6) δ 13.14 (s, 1H), 10.32 (s, 1H), 9.05 (s, 1H), 8.49 (s, 2H), 8.30 (d, J = 14.9 Hz, 2H), 7.63 (s, 2H), 7.55 (s, 2H), 4.67 (s, 2H).
[0373] Step 4: 4-(2-(6-bromopyridin-3-yl)hydrazono)-3-(hydroxyimino)-1-(pyridin-3-yl)pyrrolidin-2-one (0.7 g, 1.865 mmol) from step 3 was refluxed in acetic anhydride (5 ml) for 30 min. The dark brown solution was then poured into cold saturated sodium bicarbonate solution and the precipitated dark product was filtered, washed with water and air-dried to give a brown solid (0.456 g, 100%, LCMS), LC / MS [M+H] 358.8.
[0374] (Preparation Example 6)
[0375] [ka]
[0376] Step 1: A suspension of (4-methoxyphenyl)methanamine (2.7 g, 0.0196 mol) in MeOH (300 mL) was treated with ethyl 1-(6-chloropyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate (5 g, 0.018 mol) and AcOH (1.2 g, 0.019 mol) was added. The resulting mixture was heated to reflux for 4 h. The mixture was cooled to 0° C. and sodium cyanoborohydride (2.36 g, 0.037 mmol) was added in portions. The reaction mixture was stirred at room temperature overnight. Aqueous NaHCO3 was added and the solvent was then evaporated. The resulting mixture was extracted three times with DCM, dried over MgSO4 and the solvent was removed in vacuo to give the crude product (7.4 g mixture of CO2Et and CO2Me esters) which was used in the next step without purification.
[0377] Step 2: Ethyl 1-(6-chloropyridin-3-yl)-4-(((4-methoxybenzyl)amino)methyl)-1H-pyrazole-3-carboxylate (7.4 g, 0.019 mol) from step 1 was dissolved in THF and 1 mL of an aqueous solution of KOH (3.2 g, 0.057 mol) was added at room temperature. The mixture was stirred overnight. The solvent was evaporated and 70 ml of water was added. Acid was added to the reaction solution to adjust the pH to 5. The resulting mixture was extracted three times with CH2Cl2 / MeOH (80 / 20), dried over MgSO4, and the solvent was removed in vacuo to give the crude product (5.4 g, 92% purity), which was used in the next step. LC / MS [M+H] 373.0.
[0378] Step 3: 1-(6-chloropyridin-3-yl)-4-(((4-methoxybenzyl)amino)methyl)-1H-pyrazole-3-carboxylic acid (5.4 g, 0.014 mol) from step 2 was dissolved in acetonitrile (200 mL) and DMF (50 ml). NMI (3.7 g, 0.045 mol, 3.1 eq.) was added followed by TCFH (4.9 g, 0.017 mol, 1.2 eq.). The reaction mixture was stirred at room temperature for 3 days, then the solvent was evaporated and water was added. The resulting mixture was extracted three times with CHCl / MeOH (80 / 20), dried over MgSO and the solvent was removed in vacuo to give a residue which was washed with water and MeOH to give the product (1.5 g, 90% purity), LC / MS [M+H] 355.0.
[0379] Step 4: To a solution of 2-(6-chloropyridin-3-yl)-5-(4-methoxybenzyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (1 g, 0.0028 mol) from step 3 in acetonitrile:water (60 mL:20 mL) was added CAN (6.18 g, 0.0011 mol) and the mixture was stirred at room temperature for 3 h. The acetonitrile was removed under vacuum and the reaction mixture was then extracted with ethyl acetate (5×30 mL). The organic layer was washed with brine, dried over sodium sulfate, and concentrated to give the crude product, which was recrystallized from methanol to give 0.6 g of the product as a yellow solid. LC / MS [M+H] 235.0.
[0380] Step 5: 2-(6-chloropyridin-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (0.3 g, 0.0013 mol), 5-iodothiazole (0.4 g, 0.0019 mol), Cs2CO3 (1.25 g, 0.0038 mol, 3 eq.) and CuI (0.25 g, 0.0013 mol, 1 eq.) from step 4 were mixed in 15 ml of dry dioxane. trans-N,N'-dimethylcyclohexane-1,2-diamine (CyDMEDA) (0.18 g, 0.0013 mol, 1 eq.) and proline (0.15 g, 0.0013 mol, 1 eq.) were then added in one portion. The reaction mixture was sealed and heated at 110 °C with shaking for 24 h. The mixture was cooled and the solvent was evaporated under high vacuum. The residue was dissolved in H2O. An aqueous solution of NaHSO4 was added and the solid was filtered, washed with NH3×H2O, washed once with IPS and dried under reduced pressure to give the crude product (300 mg, 79% by LCMS). The product as the TFA salt was crystallized twice using THF to give 150 mg TFA salt (100%, LCMS). LC / MS [M+H] 318.0.
[0381] (Preparation Example 7)
[0382] [ka]
[0383] An oven-dried screw-capped vial was charged with the product of Step 4 of Preparation 6 (350 mg, 1.5 mmol), 5-bromo-2-methylthiazole (530 mg, 3.0 mmol), K2CO3 (415 mg, 3.0 mmol), DMEDA (56 mg, 0.30 mmol), CuI (56 mg, 0.30 mmol) and 1,4-dioxane (17.5 mL) under argon. The mixture was then degassed with argon for 15 min and heated to 100° C. for 12 h. The progress of the reaction was monitored by TLC. The reaction mixture was then quenched with water (15 mL) and the product was extracted three times with DCM (25 mL×3). The extract was dried over Na2SO4, concentrated and purified by chromatography on silica gel (60-120 mesh) eluting with 3% MeOH in DCM to give 2-(6-chloropyridin-3-yl)-5-(2-methylthiazol-5-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one as a yellow solid (110 mg, 22%). H NMR (DMSO-d6) δ 9.04 (d, 1H), 8.80 (s, 1H), 8.42 (dd, 1H), 7.76 (d, 1H), 7.55 (s, 1H), 5.01 (s, 2H), 2.61 (s, 3H). LCMS: 385.1 [M+H]+
[0384] (Preparation Example 8)
[0385] [ka]
[0386] Step 1: To a stirred solution of fluoroethanol (9.5 mL, 164 mmol) and NaOH (6.04 g, 151 mmol) in THF (500 mL) under N2, 2-chloro-5-nitropyridine (20 g, 126 mmol) was added portionwise and stirred at 70 °C for 18 h. The progress of the reaction was monitored by TLC. The reaction mixture was then quenched with water (100 mL) and the product was extracted three times with EtOAc (100 mL × 3). The combined organic layers were dried over Na2SO4, concentrated and purified by chromatography on silica gel (100-200 mesh) eluting with 7% EtOAc in hexane to give 2-(2-fluoroethoxy)-5-nitropyridine as a yellow solid (12.6 g, 54%). 1 H NMR (DMSO-d6) δ 9.09 (d, 1H), 8.51 (dd, 1H), 7.11 (d, 1H), 4.84 (dd, 1H), δ 4.74 (dd, 1H), 4.69 (dd, 1H), 4.63 (t, 1H).
[0387] Step 2: Into an oven-dried one-neck round-bottom flask, 2-(2-fluoroethoxy)-5-nitropyridine (7.5 g, 40.3 mmol), MeOH (300 mL, 40 vol.) and NH4COOH (12.7 g, 202 mmol.) were added at 0° C. The reaction mixture was stirred at 0° C. for 30 min. Then, Pd / C (2.2 g, 30% w / w) (300 mg, 0.48 mmol.) was added portionwise to the above mixture and stirred at room temperature for 4 h. The reaction mixture was then filtered through a celite bed and washed twice with methanol (2×50 mL). The filtrate was evaporated to give crude 6-(2-fluoroethoxy)pyridin-3-amine (5.64 g, 90%), which was used directly in the next step without further purification. 1 H NMR (DMSO-d6) δ 7.48 (d, 1H), 7.02 (dd, 1H), 6.59 (d, 1H), 4.79 (s, 2H), δ 4.73 (t, 1H), 4.63 (t, 1H), 4.36 (t, 1H), 4.30 (t, 1H). MS (ESI): 156.86 [M+H]+
[0388] Step 3: A solution of sodium nitrite (0.97 g, 14.1 mmol) was added dropwise via addition funnel to a solution of 6-(2-fluoroethoxy)pyridin-3-amine (2.0 g, 156.25 mmol) in 6.0 M HCl (222 mL) at 0° C. The reaction mixture was stirred at −10° C. to 0° C. for 0.5 h. Then, a solution of tin(II) chloride (6.9 g, 31 mmol) in 6.0 M HCl (22 mL) was added dropwise via addition funnel to the reaction mixture. The reaction mixture was stirred at −10° C. to 0° C. for an additional 4 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture basified to pH 10 with 40% aqueous KOH (60 mL) was added dropwise via addition funnel to the reaction mixture at −5.0° C. to 0° C. To the crude reaction mixture was added DCM (80 mL) and the reaction mixture was stirred at −10° C. for 15 min. The layers were separated. The organic layer was collected and the procedure was repeated twice. The organic layers were combined, dried over Na2SO4, and concentrated under vacuum. The resulting mass was washed with hexane (20 mL) to give the product 2-(2-fluoroethoxy)-5-hydrazinylpyridine as a brown solid (1.58 g, 75%). 1 H NMR (DMSO-d6) δ 7.67 (d, 1H), 7.21 (dd, 1H), 6.66 (d, 1H), 6.46 (s, 1H), 4.74 (t, 1H), 4.64 (t, 1H), 4.39 (t, 1H), 4.33 (dd, 1H), 3.97 (s, 2H). MS(ESI):171.94 [M]+
[0389] Step 4: A solution of 2-(2-fluoroethoxy)-5-hydrazinylpyridine (1.5 g, 8.8 mmol) in ethanol (15 mL) was cooled to 0° C., and a solution of commercially available ethyl 2-oxopropanoate (1.16 mL, 10.5 mmol) in ethanol (3.0 mL) was added dropwise at 0° C. for 15 min. The mixture was then stirred at room temperature for 4 h. After completion of the reaction, it was evaporated to give ethyl (Z)-2-(2-(6-(2-fluoroethoxy)pyridin-3-yl)hydrazinylidene)propanoate as a white solid (1.8 g, 78%), which was used directly in the next step. 1 H NMR (DMSO-d6) δ 9.93 (s, 1H), 8.07 (d, 1H), 7.65 (dd, 1H), 6.85 (d, 1H), 4.77 (t, 1H), 4.68 (t, 1H), 4.47 (t, 1H), 4.40 (t, 1H), 4.18 (q, 2H), 2.04 (s, 3H), 1.26 (t, 3H). MS (ESI): 270.15 [M+H]+
[0390] Step 5: POCl3 (3.3 mL, 22 mmol) was added to DMF (15 mL) at 0° C. under constant stirring under ice-cooled condition (0-5° C.) in a round bottom flask. The intermediate ethyl (Z)-2-(2-(6-(2-fluoroethoxy)pyridin-3-yl)hydrazinylidene)propanoate (1.8 g, 6.6 mmol) in DMF (3.6 mL, 2.0 vol) was added to the Vilsmeier-Haack reagent and stirred for 1 h, and the reaction mixture was kept at 70° C. for 4 h. After completion, the mixture was poured into crushed ice with constant manual stirring. After neutralization with K2CO3 solution (10 mL), ethyl acetate (50 mL) was added. The organic phase was separated and the aqueous phase was extracted with EtOAc (40 mL×3). The combined organic solution was washed with water (25 mL) and brine (25 mL), dried and concentrated. The product, ethyl 1-(6-(2-fluoroethoxy)pyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate, was purified by recrystallization from ethanol to give the title compound (1.4 g, 70%). 1 H NMR (DMSO-d6) δ 10.29 (s, 1H), 9.20 (s, 1H), 8.74 (d, 1H), 8.28 (dd, 1H), 7.09 (d, 1H), 4.83 (t, 1H), 4.73 (t, 1H), 4.61 (t, 1H), 4.55 (dd, 1H), 4.42 (q, 2H), 1.36 (t, 3H). MS (ESI): 308.11 [M+H]+
[0391] Step 6: A suspension of (4-methoxyphenyl)methanamine (0.4 g, 2.9 mmol) in MeOH (60 mL) was treated with ethyl 1-(6-(2-fluoroethoxy)pyridin-3-yl)-4-formyl-1H-pyrazole-3-carboxylate (1.0 g, 3.2 mmol) and glacial AcOH (0.9 mL) was added. The resulting mixture was heated to reflux for 4 h. The mixture was cooled to 0° C. and sodium cyanoborohydride (0.38 g, 6.0 mmol) was added in portions. The reaction mixture was stirred at room temperature for 12 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with saturated aqueous NaHCO3 (10 mL) and the product was extracted with DCM (40 mL×3). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the residual ethyl 1-(6-(2-fluoroethoxy)pyridin-3-yl)-4-(((4-methoxybenzyl)amino)methyl)-1H-pyrazole-3-carboxylate (1.3 g, crude) mixture of CO2Et and CO2Me esters, which was used in the next step without purification. 1H NMR (DMSO-d6) δ 8.65 (t, 1H), 8.48 (d, 1H), 8.21 (td, 1H), 7.27 (m, 2H), 7.06 (d, 1H), 6.88 (dd, 3H), 4.82 (t, 1H), 4.73 (t, 1H), 4.59 (t, 1H), 4.53 (t, 1H), 4.29 (q, 3H), 3.82 (s, 2H), 3.79 (s, 2H), 3.73 (s, 4H), 3.70 (d, 1H), 3.68 (s, 2H), 1.29 (t, 1H). MS (ESI): 429.33 [M+H]+
[0392] Step 7: The compound ethyl 1-(6-(2-fluoroethoxy)pyridin-3-yl)-4-(((4-methoxybenzyl)amino)methyl)-1H-pyrazole-3-carboxylate (0.5 g, 1.2 mmol) was dissolved in THF (15 mL) and 2.0 mL of an aqueous solution of KOH (0.2 g, 3.5 mmol) was added. The reaction mixture was stirred at room temperature for 12 h. The progress of the reaction was monitored by TLC. The mixture was then cooled to 0 °C and treated with 2 M aqueous HCl until the pH reached a maximum of 3-4. The biphasic mixture was stirred for 5 min and the layers were separated. The aqueous layer was further extracted with 10% MeOH in DCM (3×20 mL) and the combined organic layers were dried over Na2SO4 and concentrated in vacuo to give 1-(6-(2-fluoroethoxy)pyridin-3-yl)-4-(((4-methoxybenzyl)amino)methyl)-1H-pyrazole-3-carboxylic acid as a yellow solid (330 mg, 70%) which was used directly in the next step. 1 H NMR (DMSO-d6) δ 10.97 (s, 1H), 8.60 (d, 1H), 8.52 (s, 1H), 8.16 (dd, 1H), 7.40 (d, 2H), 7.06 (d, 1H), 6.98 (d, 2H), 4.82 (t, 1H), 4.72 (t, 1H), 4.59 (t, 1H), 4.53 (t, 1H), 4.06 (d, 4H), 3.77 (s, 3H). MS (ESI): 401.29 [M+H]+
[0393] Step 8: The compound 1-(6-(2-fluoroethoxy)pyridin-3-yl)-4-(((4-methoxybenzyl)amino)methyl)-1H-pyrazole-3-carboxylic acid (0.3 g, 0.75 mmol) was dissolved in acetonitrile (10.5 mL). DMF (3.0 mL) and NMI (0.19 g, 2.3 mmol) were then added. The reaction mixture was stirred at room temperature for 30 minutes. A clear solution was observed. TCFH (0.25 g, 0.9 mmol) was then added and the reaction was stirred at room temperature for 3 days. After completion of the reaction as monitored by TLC, the reaction mixture was quenched with ice-cold water (5 mL). The crude reaction was filtered through a Buchner funnel and the resulting mass was washed with water and MeOH (4:1, 3 mL) to give the product 2-(6-(2-fluoroethoxy)pyridin-3-yl)-5-(4-methoxybenzyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one as a yellow solid (240 mg, crude), which was used directly in the next step without further purification. 1 H NMR (DMSO-d6) δ 8.67 (d, 1H), 8.46 (s, 1H), 8.22 (q, 1H), 7.22 (d, 2H), 7.07 (d, 1H), 6.92 (m, 2H), 4.82 (t, 1H), 4.73 (t, 2H), 4.62 (s, 2H), 4.59 (t, 2H), 4.53 (d, 2H), 4.29 (s, 2H), 3.73 (s, 3H), 3.67 (s, 2H). MS (ESI): 383.22 [M+H]+
[0394] Step 9: To a solution of intermediate 2-(6-(2-fluoroethoxy)pyridin-3-yl)-5-(4-methoxybenzyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (0.2 g, 0.52 mmol) in acetonitrile:water (3:1, 16 mL) was added CAN (1.1 g, 4.0 mmol) and the mixture was stirred at room temperature for 3 h. Acetonitrile was removed under vacuum and the reaction mixture was then extracted with ethyl acetate (5×10 mL). The organic layer was washed with brine (5 mL), dried over Na2SO4, and concentrated to give the crude product, which was recrystallized from methanol to give the product 2-(6-(2-fluoroethoxy)pyridin-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (45 mg, 27%) as a yellow solid. 1 H NMR (DMSO-d6) δ 8.67 (d, 1H), 8.56 (s, 1H), 8.48 (s, 1H), 8.22 (dd, 1H), 7.07 (d, 1H), 4.83 (t, 1H), 4.73 (t, 1H), 4.60 (t, 2H), 4.54 (t, 1H), 4.31 (s, 2H). MS (ESI): 263.10 [M+H]+
[0395] Example 1
[0396] [ka]
[0397] To a solution of 2-(6-chloropyridin-3-yl)-5-(pyridin-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (0.3 g, 0.00032 mol) as HCl salt and (R)-3-fluoropyrrolidine (0.23 g, 0.0019 mol) in 3 ml DMSO was added CsF (0.29 g, 0.0019 mol) and the resulting mixture was heated to 110° C. for 16 h. After monitoring the completion of the reaction by TLC, the mixture was cooled to room temperature and diluted with water. The resulting mixture was extracted twice with ethyl acetate. The combined organic layers were washed twice with water, dried over MgSO4, and the solvent was removed in vacuum to give a residue (80 mg). The compound was purified by HPLC to give 4.2 mg of 2-{6-[(3R)-3-fluoropyrrolidin-1-yl]pyridin-3-yl}-5-(pyridin-3-yl)-2H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-6-one as a beige solid. LC / MS [M+H] 365.0 1 H NMR (600 MHz, DMSO-d6) δ 9.05 (d, 1H), 8.60 (d, 1H), 8.50 (s, 1H), 8.37 (dd, 1H), 8.36 - 8.26 (m, 1H), 8.01 (dd, 1H), 7.46 (dd, 1H), 6.67 (d, 1H), 5.46 (d, 1H), 5.00 (s, 2H), 3.87 - 3.58 (m, 3H), 3.47 (m, 1H), 2.35 - 2.08 (m, 2H).
[0398] (Examples 2 to 16) Following the SNAr reaction procedure described in Example 1, the following compounds were prepared using the heteroaryl halide and amine starting materials shown in Table 1 below.
[0399] [Table 2A]
[0400] [Table 2B]
[0401] [Table 2C]
[0402] [Table 2D]
[0403] [Table 2E]
[0404] [Table 2F]
[0405] [Table 2G]
[0406] (Example 17)
[0407] [ka]
[0408] Step 10: An oven-dried screw-capped vial was charged with 2-(6-(2-fluoroethoxy)pyridin-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (40 mg, 0.15 mmol), 3-iodopyridine (62 mg, 0.3 mmol), K2CO3 (42 mg, 0.3 mmol), DMEDA (5.0 mg, 0.06 mmol), CuI (5.0 mg, 0.03 mmol) and 1,4-dioxane (2.0 mL) under argon. The mixture was then degassed with argon for 15 min and heated to 100 °C for 12 h. The progress of the reaction was monitored by TLC. The reaction mixture was then quenched with water (3 mL) and the product was extracted with DCM (10 mL x 3). The extract was dried over Na2SO4, concentrated and purified by chromatography on silica gel (60-120 mesh) eluting with 3% MeOH in DCM to give 2-(6-(2-fluoroethoxy)pyridin-3-yl)-5-(pyridin-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one as a yellow solid (16 mg, 31%). 1 H NMR (DMSO-D6) δ 9.07 (d, 1H), 8.73 (dd, 1H), 8.66 (s, 1H), 8.40 (dd, 1H), 8.30 (m, 2H), 7.49 (m, 1H), 7.11 (dd, 1H), 5.05 (s, 2H), 4.85 (m, 1H), 4.73 (m, 1H), 4.62 (m, 1H), 4.54 (m, 1H). LCMS: 340.25 [M+H]+
[0409] (Examples 18 to 20) Following the coupling reaction procedures described in Example 17, the following compounds were prepared using the heteroaryl halide and amide starting materials shown in Table 2 below.
[0410] [Table 3A]
[0411] [Table 3B]
[0412] Description of the biological assays and corresponding results 1. Preparation of alpha-synuclein (a-syn) aggregates from human Parkinson's disease (PD) brains The procedure was adapted from the protocol described in Spillantini et al., 1998. Frozen tissue blocks from PD donors were thawed on ice and homogenized using a glass Dounce homogenizer. The homogenate was then centrifuged at 11,000×g (12,700 RPM) in an ultracentrifuge (Beckman, XL100K) using a pre-cooled 70.1 rotor (Beckman, 342184) for 20 minutes at 4° C. The pellet was resuspended in extraction buffer [10 mM Tris-HCl pH 7.4, 10% sucrose, 0.85 mM NaCl, 1% protease inhibitors (Calbiochem 539131), 1 mM EGTA, 1% phosphatase inhibitors (Sigma P5726 and P0044)] and centrifuged at 15,000 x g (14,800 RPM, 70.1 Ti rotor) for 20 minutes at 4°C. The pellet was discarded and Sarkosyl (20% stock solution, Sigma L7414) was added to the supernatant to a final concentration of 1% for 1 hour at room temperature. The solution was then centrifuged at 100,000 x g (38,000 RPM, 70.1 Ti rotor) for 1 hour at 4°C. The pellet, containing abundant alpha-synuclein aggregates, was resuspended in PBS and stored at -80°C until use.
[0413] 2. Micro-radiobinding competition assay for determination of binding affinity Alpha-synuclein aggregates from PD brains were spotted on microarray slides. Slides were incubated with 6 nM, 20 nM or 30 nM of tritiated reference alpha-synuclein ligand and 1 μM and 100 nM of example compounds (non-radiolabeled). In some cases, non-radiolabeled example compounds were further evaluated at a range of different concentrations varying from 0.05 nM to 2 μM. After incubation, slides were washed and scanned by a real-time autoradiography system (BeaQuant, ai4R). Quantification of the signal was performed by using Beamage image analysis software (ai4R). Non-specific signal was determined with an excess of non-radiolabeled reference alpha-synuclein ligand (2 μM) and specific binding was calculated by subtracting non-specific signal from total signal. Competition was calculated as a percentage, where 0% was defined as specific binding in the presence of vehicle and 100% was defined as the value obtained in the presence of an excess of non-radiolabeled reference alpha-synuclein ligand. i Values were calculated in GraphPad Prism7 by applying nonlinear regression curve fitting using a one-site specific binding model. All measurements were performed with at least two technical replicates. For compounds tested in more than one experiment, the mean or K of independent experimental replicates is reported. i Report the value.
[0414] Results: Exemplary compounds were evaluated for their potency in competing with the binding of tritiated reference alpha-synuclein ligands to alpha-synuclein aggregates from PD patient brains. The results of the microradio binding competition assay for the exemplary compounds tested are shown in Table 2 (Table 4) as % competition at 1 μM and 100 nM. Table 2 shows the K i The values are also shown.
[0415] [Table 4]
[0416] Table 2: Evaluation of binding affinity to alpha-synuclein aggregates derived from human PD brain by microradio binding competition assay. Percent competition (%) over tritiated reference alpha-synuclein ligand in the presence of 1 μM and 100 nM of exemplary compounds 1-12. Ki values are also shown for selected exemplary compounds. As shown in Table 2, exemplary compounds 1-12 of the present invention show strong binding to alpha-synuclein aggregates derived from PD brain.
Claims
1. Formula (I) 【Chemistry 1】 (In the formula, 【Chemistry 2】 is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 But -NH 2 , -N(C 1 ~C 4 Alkyl) 2 or -NH(C 1 ~C 4 alkyl), C 1 ~C 4 The alkyl is optionally substituted with at least one halo, or -NH 2 or -NH(C 1 ~C 4 At least one H attached to an N in the alkyl group is replaced by halo; or R 1 But, HaroC 1 ~C 4 is an alkoxy; R 2 is optionally -halo, -OH, -CN, -N(C 1 ~C 4 Alkyl) 2 , -NH(C 1 ~C 4 Alkyl), -N(HaloC 1 ~C 4 Alkyl) 2 , -NH(HaloC 1 ~C 4 Alkyl), HaloC 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy and -C 1 ~C 4 and n is 0, 1 or 2. A 5- or 6-membered heteroaryl substituted with 1 or 2 substituents independently selected from alkyl, or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
2. The compound according to claim 1, 【Chemistry 3】 (In the formula, 【Chemistry 4】 is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 6-membered heterocyclyl optionally substituted with at least one halo; or R 1 But -NH 2 , -N(C 1 ~C 4 Alkyl) 2 or -NH(C 1 ~C 4 alkyl), C 1 ~C 4 the alkyl is optionally substituted with at least one halo; R 2 optionally -halo, -OH, -CN, -N(C 1 ~C 4 Alkyl) 2 , -NH(C 1 ~C 4 Alkyl), -N(HaloC 1 ~C 4 Alkyl) 2 , -NH(HaloC 1 ~C 4 Alkyl), HaloC 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy and -C 1 ~C 4 and n is 0, 1 or 2. A 5- or 6-membered heteroaryl substituted with 1 or 2 substituents independently selected from alkyl, or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
3. Formula (IIa) or (IIb) 【Chemistry 5】 3. The compound of claim 1 or 2, or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, having the formula:
4. R 1 is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo.
5. R 1 But, 【Chemistry 6】 (In the formula, R 1a is a 4- to 7-membered heterocyclyl selected from H or halo, preferably halo.
6. R 1 But, 【Chemistry 7】 6. The compound according to claim 4 or 5, wherein the heterocyclyl is a 4-, 5- or 7-membered heterocyclyl selected from:
7. R 1 But, F.C. 1 ~C 4 2. The compound of claim 1 which is alkoxy.
8. R 2 But, 【Chemistry 8】 (In the formula, R 2a -Halo, -OH, -CN, -N(C 1 ~C 4 Alkyl) 2 , -NH(C 1 ~C 4 Alkyl), -N(HaloC 1 ~C 4 Alkyl) 2 , -NH(HaloC 1 ~C 4 Alkyl), HaloC 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy and -C 1 ~C 4 independently selected from alkyl, R 2b But, -H, Halo C 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy and -C 1 ~C 4 alkyl, 8. The compound according to claim 1, wherein s is 0, 1 or 2.
9. R 2 But, 【Chemistry 9】 (In the formula, R 2a But -C 1 ~C 4 Alkoxy and -C 1 ~C 4 independently selected from alkyl, R 2b However, -H and -C 1 ~C 4 alkyl, 9. The compound of claim 8, wherein s is 0, 1 or 2).
10. The compound is 【Chemistry 10A】 【Chemistry 10B】 【Chemistry 10C】 2. The compound of claim 1, or a detectably labeled compound, stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof, selected from:
11. 11. The compound according to any one of claims 1 to 10, wherein the compound is a detectably labeled compound.
12. The detectably labeled compound may be a radioisotope, preferably 2 H, 3 H or 18 12. The compound of claim 11, comprising a detectable label selected from F.
13. A diagnostic composition comprising a compound according to any one of claims 1 to 12 and, optionally, at least one pharma- ceutically acceptable excipient, carrier, diluent and / or adjuvant.
14. A compound according to claim 11 or 12, or a diagnostic composition according to claim 13, for use in imaging alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
15. A compound according to claim 11 or 12, or a diagnostic composition according to claim 13, for use in positron emission tomography imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites.
16. 16. The compound for use or the diagnostic composition for use according to claim 14 or 15, wherein the use is for in vitro imaging, ex vivo imaging or in vivo imaging, preferably the use is for in vivo imaging, more preferably the use is for brain imaging.
17. A compound according to claim 11 or 12, or a diagnostic composition according to claim 13, for use in a diagnostic method.
18. The method of diagnosis is for a disease, disorder or abnormality associated with, or a predisposition to, alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, the disease, disorder or abnormality optionally being Parkinson's disease (including sporadic, familial with alpha-synuclein mutations, familial with non-alpha-synuclein mutations, pure autonomic failure or Lewy body dysphagia), SNCA duplication carriers, dementia with Lewy bodies (LBD), Dementia with Lewy Bodies (DLB) (including "pure" Lewy body dementia), Parkinson's disease dementia (PDD), Diffuse Lewy Body Disease (DLBD), Alzheimer's disease, Sporadic Alzheimer's disease, Familial Alzheimer's disease with APP mutations, Familial Alzheimer's disease with PS-1, PS-2 or other mutations, Familial British Dementia, Lewy body variant of Alzheimer's disease, Down's syndrome, Multiple System Atrophy (MSA) (including Shy-Drager syndrome, Striatonigral degeneration or Oncogene syndrome) Reeve pontocerebellar atrophy), traumatic brain injury, chronic traumatic encephalopathy, dementia pugilistica, tauopathies (including Pick's disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, Niemann-Pick disease type C1, frontotemporal dementia with parkinsonism linked to chromosome 17), Creutzfeldt-Jakob disease, Huntington's disease, motor neuron disease, amyotrophic lateral sclerosis (including sporadic, familial or Guam ALS-dementia complex), neuroaxonal dystrophies, and brain iron accumulation.
18. The compound for use or diagnostic composition for use according to claim 17, wherein the compound for use or the diagnostic composition for use is selected from: associated neurodegeneration type 1 (including Hallervorden-Spatz syndrome), prion diseases, ataxia-telangiectasia, Meige syndrome, subacute sclerosing panencephalitis, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, Gaucher disease, Krabbe disease, and other lysosomal storage diseases (including Kufor-Rakeb syndrome and Sanfilippo syndrome) and rapid eye movement (REM) sleep behavior disorder.
19. 19. The compound for use, or the diagnostic composition for use, according to claim 18, wherein the disease is Parkinson's disease.
20. 19. The compound for use, or the diagnostic composition for use, according to claim 18, wherein the disease is multiple system atrophy.
21. 19. The compound for use or diagnostic composition for use according to claim 18, wherein the disease is dementia with Lewy bodies.
22. 19. The compound for use, or the diagnostic composition for use, according to claim 18, wherein the disease is Parkinson's disease dementia.
23. 19. The compound for use or the diagnostic composition for use according to claim 18, wherein the disease is SNCA duplication carrier.
24. 19. The compound for use, or the diagnostic composition for use, according to claim 18, wherein the disease is Alzheimer's disease.
25. 25. A compound for use, or a diagnostic composition for use, according to any one of claims 14 to 24, wherein the use is in a human.
26. 1. A method for diagnosing a disease, disorder or abnormality associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a subject, comprising: (a) administering to a subject a compound according to any one of claims 1 to 12 or a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12. (b) binding the compound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites; and (c) detecting compounds that bind to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites. The method includes:
27. (d) generating an image representative of the location and / or amount of compound bound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites. The method of diagnosis according to claim 26, further comprising:
28. 1. A method of positron emission tomography (PET) imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject, comprising: (a) administering to a subject a compound according to any one of claims 1 to 12 or a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites; and (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, by acquiring positron emission tomography (PET) images of the subject's tissue. The method includes:
29. 29. A method for positron emission tomography (PET) imaging of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject according to claim 28, wherein the tissue is a tissue of the central nervous system (CNS), an eye tissue, a tissue of a peripheral organ or a brain tissue, preferably the tissue is a brain tissue.
30. 1. A method for detecting, and optionally quantifying, alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a tissue of a subject, comprising: (a) contacting a sample or a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to any one of claims 1 to 12 or with a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, using positron emission tomography; and (d) optionally quantifying the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites. The method includes:
31. 1. A method of collecting data for diagnosing a disease, disorder, or abnormality associated with alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample or a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to any one of claims 1 to 12 or with a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region. The method includes:
32. 1. A method of collecting data to determine a predisposition to a disease, disorder, or condition associated with alpha-synuclein aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample or a specific body part or region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to any one of claims 1 to 12 or with a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; and (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region. The method includes:
33. 1. A method of collecting data for prognosticating a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample, a specific body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to any one of claims 1 to 12 or with a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The method includes:
34. 1. A method of collecting data to monitor the progression of a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in a patient, comprising: (a) contacting a sample, a specific body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to any one of claims 1 to 12 or with a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The method includes:
35. 1. A method of collecting data to predict responsiveness to treatment with a pharmaceutical agent in a patient suffering from a disease, disorder or condition associated with alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, comprising: (a) contacting a sample, a specific body part or a body region suspected of containing alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with a compound according to any one of claims 1 to 12 or with a diagnostic composition according to claim 13 comprising a compound according to any one of claims 1 to 12; (b) binding the compound to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (c) detecting compounds that bind to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; (d) optionally correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and (e) optionally repeating steps (a) through (c), and, if present, optional step (d), at least once. The method includes:
36. Optionally, correlating the presence or absence of a compound that binds to alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, with the presence or absence of alpha-synuclein aggregates, including but not limited to, Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region, comprising: - determining the amount of the compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites; - correlating the amount of the compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, with the amount of alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region; and - optionally comparing the amount of compound that binds to alpha-synuclein aggregates, including but not limited to Lewy bodies and / or Lewy neurites, in the sample or in a particular body part or region with a normal control value in a healthy control subject.
36. The method of any one of claims 31 to 35, comprising:
37. Formula (III-F) 【Chemistry 11】 (In the formula, 【Chemistry 12】 is a 6-membered heteroaryl; X is CH or N; R 1F is a 4- to 7-membered heterocyclyl; or R 1F But -N(C 1 ~C 4 Alkyl) 2 or -NH(C 1 ~C 4 alkyl), or R 1F But, C 1 ~C 4 is an alkoxy; R 2 is optionally -halo, -OH, -CN, -N(C 1 ~C 4 Alkyl) 2 , -NH(C 1 ~C 4 Alkyl), -N(HaloC 1 ~C 4 Alkyl) 2 , -NH(HaloC 1 ~C 4 Alkyl), HaloC 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy and -C 1 ~C 4 is a 5- or 6-membered heteroaryl substituted with 1 or 2 substituents independently selected from alkyl; LG is a leaving group, n is at least 1), or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
38. LG is bromo, chloro, iodo, C 1 ~C 4 Alkyl sulfonates and C 6 ~C 10 aryl sulfonates, C 6 ~C 10 The aryl sulfonate is optionally -CH 3 OR -NO 2 38. The compound of formula (III-F) of claim 37, optionally substituted with:
39. Formula (III-H) 【Chemistry 13】 (In the formula, 【Chemistry 14】 is a 6-membered heteroaryl; X is CH or N; R 1 is a 4- to 7-membered heterocyclyl optionally substituted with at least one halo; or R 1 But -NH 2 , -N(C 1 ~C 4 Alkyl) 2 or -NH(C 1 ~C 4 alkyl), or R 1 But Fluoro C 1 ~C 4 is an alkoxy; R 2 is optionally -halo, -OH, -CN, -N(C 1 ~C 4 Alkyl) 2 , -NH(C 1 ~C 4 Alkyl), -N(HaloC 1 ~C 4 Alkyl) 2 , -NH(HaloC 1 ~C 4 Alkyl), HaloC 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy and -C 1 ~C 4 is a 5- or 6-membered heteroaryl substituted with 1 or 2 substituents independently selected from alkyl; m is 0, 1 or 2; p is 0, 1 or 2; Z is bromo, chloro or iodo; -N(C 1 ~C 4 Alkyl) 2 , -NH(C 1 ~C 4 Alkyl), -N(HaloC 1 ~C 4 Alkyl) 2 , -NH(HaloC 1 ~C 4 Alkyl), HaloC 1 ~C 4 Alkyl, haloC 1 ~C 4 Alkoxy, -C 1 ~C 4 Alkoxy or -C 1 ~C 4 The alkyl optionally contains at least one Z; provided that the compound of formula (III-H) contains at least one Z, or a stereoisomer, racemic mixture, pharma- ceutically acceptable salt, hydrate or solvate thereof.
40. The compound of formula (III-F) according to claim 37 or 38, 18 To be replaced by F 18 13. A process for preparing a compound according to claim 11 or 12, comprising reacting with an F-fluorinating agent.
41. 18 F-fluorinating agent is K 18 F, Rb 18 F, Cs 18 F, Na 18 F, Kryptofix[222]K 18 F, 18 F Tetra (C 1~6 Alkyl) ammonium salts and tetrabutylammonium [ 18 41. The method of claim 40, wherein the compound is selected from the group consisting of [F] fluoride.
42. Compound of formula (III-H) according to claim 39, 3 13. A method for preparing a compound of claim 11 or 12, comprising reacting with a H radiolabeling agent.
43. 13. A compound according to any one of claims 1 to 12 for use as an in vitro analytical standard or an in vitro screening tool.
44. 13. A test kit for detecting and / or diagnosing a disease, disorder or abnormality associated with alpha-synuclein aggregates, comprising at least one compound as defined in any one of claims 1 to 12.
45. 40. A kit for preparing a radiopharmaceutical preparation, comprising a sealed vial containing at least one compound as defined in any one of claims 37 to 39.
Citation Information
Patent Citations
Improvement in the manner of constructing molds for casting butt-hinges
US2005A
Imaging Agents for Detecting Neurological Dysfunction
US20120302755A1
Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
US20140142089A1
Novel substituted azabenzoxazoles
WO2009155017A2
In vivo imaging method
WO2010063701A2
Cited By
4H-Imidazo[1,5-B]pyrazole Derivatives for Diagnostics
JP2024544539A
